Fortress Biotech (FBIO) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 09, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		48,875,087

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 82,537	$ 98,182
Accounts receivable	5,007	0
Cash deposits with clearing organizations	1,030	0
Receivables from broker-dealers and clearing organizations	1,607	0
Securities owned, at fair value	2,178	0
Inventory	123	0
Other receivables - related party	1,545	156
Prepaid expenses and other current assets	4,556	1,599
Total current assets	98,583	99,937
Property and equipment, net	6,957	309
Restricted cash	15,859	14,586
Long-term investments, at fair value	685	2,485
Intangible assets, net	1,550	1,250
Goodwill	21,739	0
Other assets	48	43
Total assets	145,421	118,610
Current liabilities
Accounts payable and accrued expenses	21,831	10,438
Accrued commissions and payroll payable	14,029	0
Deferred clearing and marketing credits	1,007	0
Interest payable	68	27
Derivative warrant liability	951	114
Other current liabilities	707	0
Total current liabilities	38,593	10,579
Notes payable, long-term (net of debt discount of $2,764 and $835 at September 30, 2016 and December 31, 2015, respectively)	24,373	23,174
Subsidiary convertible note, at fair value	3,031	0
Other long-term liabilities	4,583	584
Total liabilities	70,580	34,337
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 48,875,087 and 47,147,032 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	49	47
Additional paid-in-capital	264,397	246,955
Accumulated deficit	(227,820)	(190,156)
Total stockholders' equity attributed to the Company	36,626	56,846
Non-controlling interests	38,215	27,427
Total stockholders' equity	74,841	84,273
Total liabilities and stockholders' equity	145,421	118,610
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Discount	$ 2,764	$ 835
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	48,875,087	47,147,032
Common Stock, shares outstanding	48,875,087	47,147,032
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue
Product revenue, net	$ 429	$ 0	$ 1,793	$ 0
Revenue - from a related party	546	25	2,072	525
Total revenue	975	25	3,865	525
Cost of goods sold - product revenue	41	0	365	0
Gross margin	934	25	3,500	525
Operating expenses
Research and development	7,316	9,073	21,416	13,172
Research and development - licenses acquired	1,000	1,895	3,143	10,882
General and administrative	8,864	7,129	25,414	14,376
Total operating expenses	17,180	18,097	49,973	38,430
Loss from operations	(16,246)	(18,072)	(46,473)	(37,905)
Other income (expenses)
Interest income	89	39	241	195
Interest expense and financing fees	(689)	(350)	(1,838)	(1,033)
Change in fair value of derivative liabilities	(16)	0	(105)	0
Change in fair value of subsidiary convertible note	(13)	0	(13)	0
Change in fair value of investments	(81)	(1,472)	(1,800)	(65)
Total other expenses	(710)	(1,783)	(3,515)	(903)
Net loss	(16,956)	(19,855)	(49,988)	(38,808)
Less: net loss attributable to non-controlling interests	3,975	1,694	12,324	2,416
Net loss attributable to common stockholders	$ (12,981)	$ (18,161)	$ (37,664)	$ (36,392)
Basic and diluted net loss per common share	$ (0.32)	$ (0.46)	$ (0.94)	$ (0.93)
Weighted average common shares outstanding—basic and diluted	40,128,475	39,412,056	39,885,685	39,038,522

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Noncontrolling Interest [Member]
Balance at Dec. 31, 2015	$ 84,273	$ 47	$ 246,955	$ (190,156)	$ 27,427
Balance (in shares) at Dec. 31, 2015		47,147,032
Stock-based compensation expense	8,792	$ 0	8,792	0	0
Issuance of restricted stock	0	$ 2	(2)	0	0
Issuance of restricted stock (in shares)		1,564,241
Cashless exercise of warrants	0	$ 0	0	0	0
Cashless exercise of warrants (in shares)		12,633
Subsidiary's offering, net	11,652	$ 0	11,652	0	0
Issuance of subsidiaries' common shares for license expenses	48	0	48	0	0
Issuance of common stock for At-the-Market offering	434	$ 0	434	0	0
Issuance of common stock for At-the-Market offering (in shares)		150,556
At-the-market offering cost	(49)	$ 0	(49)	0	0
Issuance of common stock under ESPP	$ 81	$ 0	81	0	0
Issuance of common stock under ESPP (in shares)	33,958	33,958
Cancellation of restricted stock	$ 0	$ 0	0	0	0
Cancellation of restricted stock (in shares)		(33,333)
Beneficial conversion feature related to Opus Credit Facility	1,881	$ 0	1,881	0	0
Non-controlling interest in subsidiaries	0	0	(5,395)	0	5,395
Non-controlling interest related to National	17,717	0	0	0	17,717
Net loss attributable to non-controlling interests	(12,324)	0	0	0	(12,324)
Net loss attributable to common stockholders	(37,664)	0	0	(37,664)	0
Balance at Sep. 30, 2016	$ 74,841	$ 49	$ 264,397	$ (227,820)	$ 38,215
Balance (in shares) at Sep. 30, 2016		48,875,087

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net Loss	$ (49,988)	$ (38,808)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	240	17
Noncash interest expense	0	167
Amortization of debt discount	586	143
Amortization of product revenue license fee	50	0
Stock-based compensation expense	8,792	11,896
Issuance of subsidiaries' common shares for license expenses	48	0
Financing fees on Helocyte Convertible Note, at fair value	491	0
Change in fair value of investments	1,800	65
Change in fair value of derivative liabilities	105	0
Change in fair value of subsidiary convertible note	13	0
Research and development-licenses acquired, expense	3,095	9,923
Unrealized (gain) loss on marketable securities	0	(11)
Changes in operating assets and liabilities:
Accounts receivable	(118)	0
Inventory	(123)	0
Other receivables - related party	(1,389)	(69)
Prepaid expenses and other current assets	(797)	(325)
Accounts payable and accrued expenses	5,364	4,375
Interest payable	41	(2)
Other long-term liabilities	3,948	(687)
Net cash used in operating activities	(27,842)	(13,316)
Cash Flows from Investing Activities:
Net cash acquired in acquisition of National	4,626	0
Purchase of marketable securities, at fair value	0	(19,938)
Purchase of research and development licenses	(3,095)	(9,923)
Purchase of property and equipment	(5,756)	(94)
Purchase of license	(350)	(1,250)
Security deposits funded	(5)	0
Investment in Origo Acquisition Corp.	(175)	(130)
Net cash used in investing activities	(4,755)	(31,335)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	216
Proceeds from issuance of common stock under ESPP	81	26
Proceeds from subsidiary's offering	13,016	12,575
Payment of costs related to subsidiary's public offering	(1,364)	(1,507)
Proceeds from at-the-market offering	434	0
Payment of cost related to at-the-market offering	(49)	0
Payment of NSC note	(2,792)	0
Proceeds from NSC note	0	10,000
Payment of debt issuance costs associated with NSC Note	0	(855)
Proceeds from Helocyte Convertible Note	3,018	0
Payment of debt issuance costs associated with Helocyte Convertible Note	(392)	0
Proceeds from Opus Credit Facility	5,000	0
Proceeds from IDB Note	920	0
Transfer of restricted cash	(920)	0
Net cash provided by financing activities	16,952	20,455
Net decrease in cash and cash equivalents	(15,645)	(24,196)
Cash and cash equivalents at beginning of period	98,182	49,759
Cash and cash equivalents at end of period	82,537	25,563
Supplemental disclosure of cash flow information:
Cash paid for interest	238	80
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	2	1
Issuance of warrant liabilities in conjunction with NSC debt	634	0
Beneficial conversion feature related to Opus Credit Facility	1,881	0
Acquisition of National
Goodwill	(21,739)	0
Accounts receivable	(4,889)	0
Cash deposits with clearing organizations	(1,030)	0
Receivables from broker-dealers and clearing organizations	(1,607)	0
Securities owned, at fair value	(2,178)	0
Prepaid expenses and other current assets	(1,985)	0
Property and equipment, net	(1,132)	0
Restricted cash	(353)	0
Accounts payable and accrued expenses	6,079	0
Accrued commissions and payroll payable	14,029	0
Deferred clearing and marketing credits	1,007	0
Other current liabilities	707	0
Non-controlling interests	17,717	0
Net cash acquired in acquisition of National	$ 4,626	$ 0

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of our subsidiary companies, also referred to herein as the “Fortress Companies.” Additionally, the Company recently acquired a controlling interest in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”). In addition to its internal development programs, the Company leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. The Company and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. As of September 30, 2016, the Company has several consolidated Fortress Companies, some of which contain product licenses, including Avenue Therapeutics, Inc. (“Avenue”), Journey Medical Corporation (“JMC”), Coronado SO Co. (“Coronado SO”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Mustang Bio, Inc. (“Mustang”), Helocyte, Inc. (“Helocyte”) and Escala Therapeutics, Inc. (“Escala”). In addition to the foregoing companies and National, Fortress also maintains ownership positions in subsidiaries with minimal activity, including Innmune Limited, CB Securities Corporation (which holds investments classified as cash and cash equivalents in 2016 and 2015), Cellvation, Inc. and Cyprium Therapeutics, Inc. National Holdings Corporation On September 9, 2016, the Company purchased approximately 56 0.02 3.25 22.9

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 15, 2016, from which the Company derived the balance sheet data at December 31, 2015 as well as National’s Form 10-K, which was filed with the SEC on December 28, 2015, Checkpoint’s Form 10G/A, filed with the SEC on August 19, 2016, and Mustang’s Form 10G/A, filed with the SEC on October 18, 2016. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte and Cellvation, Inc. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The National assets acquired and liabilities assumed as of September 9, 2016 are based upon estimated assets and liabilities as of September 9, 2016. The Company did not include revenues or expenses from the period from September 9, 2016 to September 30, 2016 as such amounts would be immaterial to the unaudited condensed consolidated financial statements. The Company believes National’s assets acquired and liabilities assumed as of September 9, 2016 approximate such balances as of September 30, 2016. Fortress Summary of Significant Accounting Policies The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires that fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the Company’s sublicense agreement with Ovamed has been recorded at its net present value, which approximates its fair value. The amounts due to Ovamed are included in current liabilities at September 30, 2016 and at December 31, 2015 on the Condensed Consolidated Balance Sheets (see Note 12). On August 1, 2016, the Company entered into a Settlement and Forbearance Agreement with Ovamed to settle contractual obligations of approximately $ 1.9 1.1 0.8 . Consistent with the increase in JMC’s operations as of April 1, 2016 and the investment in NHLD as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. There are no significant inter-segment sales. The Company evaluates the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases. The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of September 30, 2016, the Company has $ 15.5 14.9 0.6 Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for doubtful accounts of $ 0 The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument-by-instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments in the Condensed Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. As permitted under the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 825, Financial Instruments, The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants (the “Helocyte Warrants”) issued, in connection with the Helocyte convertible note financing in June 2016 and September 2016, and determined that the Helocyte Warrants met the criteria for liability classification. Accordingly, the Company classified the Helocyte Warrants as a liability at their fair value and adjusts the instruments to fair value at each balance sheet date until the warrants are exercised or expired. Any change in the fair value of the Helocyte Warrants is recognized as “change in the fair value of warrant liabilities” in the Condensed Consolidated Statements The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the effective interest rate of the 39.49 Derivatives and Hedging The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt In accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the NSC Note transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants (see Note 7 and Note 11). At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date would be recognized as a change in fair value of derivative liabilities in the Condensed Consolidated Statements of Operations. Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit's goodwill to the carrying value of the reporting unit's goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The methodologies the Company utilizes in estimating the fair value of reporting units include market valuation methods that incorporate price-to-earnings and price-to-book multiples of comparable exchange traded companies and multiples of merger and acquisitions of similar businesses. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value. Financing costs incurred in connection with the promissory note for $ 15.0 The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Reimbursement Arrangements and Collaborative Arrangements Checkpoint is reimbursed by TG Therapeutics, Inc. (“TGTX”), a related party, for TGTX’s share of the cost of the license and product research and development under their collaboration and sublicense agreements. The gross amount of these reimbursed costs is reported as revenue in the Condensed Consolidated Statements of Operations, since the Company acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45, Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Condensed Consolidated Balance Sheets and recognized as revenue in the Condensed Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition - Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 13). The Company’s comprehensive loss is equal to its net loss for all periods presented. In January 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU No. 2016-09”) In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customer (“ASU No. 2016-10”) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, Additional Summary of Significant Accounting Policies - National The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Revenue Recognition Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients' investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National's principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National's share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers’ assets under management, may be billed monthly or quarterly and are recognized as earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services. Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuatio

National Holdings Corporation

National Holdings Corporation	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
National Holdings Corporation	3. National Holdings Corporation On April 27, 2016, the Company entered into an Agreement and Plan of Merger with National and a wholly owned subsidiary of the Company, providing for the acquisition of National (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, the Company agreed to cause its wholly owned subsidiary to commence a tender offer for all the issued and outstanding shares of National’s common stock, par value $ 0.02 3.25 7 56 22.9 ($ in thousands) Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Goodwill 21,739 Total assets 62,411 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Other current liabilities 707 Total liabilities assumed 21,822 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626 The estimated fair values of the assets acquired and liabilities assumed will be finalized as further information is received regarding these items and analysis of this information is completed. The Company preliminarily recognized $ 21.7 National's results of operations have not been included in the consolidated financial statements prospectively from the date of acquisition, because we have elected to record National’s financial results in operations under a three month lag. The following unaudited pro forma financial data assumes the acquisition had occurred at the beginning of January 1, 2015. Pro forma results have been prepared by adjusting its historical results to include National's results of operations. The unaudited pro forma results presented do not necessarily reflect the results of operations that would have resulted had the acquisition been completed at the beginning of January 1, 2015, nor does it indicate the results of operations in future periods. Additionally, the unaudited pro forma results do not include the impact of possible business model changes, nor do they consider any potential impacts of current market conditions or revenues, reduction of expenses, asset dispositions, or other factors. Three Months Ended September 30, ($ in thousands) 2016 2015 Total revenues $ 47,317 $ 42,360 Net loss attributable to common stockholders (12,962) (17,797) Loss per share: Basic $ (0.32) $ (0.45) Diluted $ (0.32) $ (0.45) Nine Months Ended September 30, ($ in thousands) 2016 2015 Total revenues $ 131,862 $ 126,976 Net loss attributable to common stockholders (37,355) (34,985) Loss per share: Basic $ (0.94) $ (0.90) Diluted $ (0.94) $ (0.90)

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations and Other Receivables	9 Months Ended
	Sep. 30, 2016
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations and Other Receivables	4. Broker-Dealers and Clearing Organizations and Other Receivables At September 9, 2016, the receivables of $ 1.6 1.8 3.1 782,000

Forgivable Loans Receivable

Forgivable Loans Receivable	9 Months Ended
	Sep. 30, 2016
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National's operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (interest rates ranging up to 9 1.8 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of September 9, 2016, no allowance for doubtful accounts was required. There were no unamortized loans outstanding attributable to registered representatives who ended their affiliation with the National broker dealer subsidiaries prior to the fulfillment of their obligation.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	6. Property and Equipment September 30, December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 436 $ 13 Furniture and fixtures 5 788 69 Leasehold improvements 5 164 21 Construction in progress (1) 15 4,733 274 Total property and equipment 6,121 377 Less: Accumulated depreciation (296) (68) Property and equipment, net $ 5,825 $ 309 (1) For build-out of the Company's new office in New York, NY. Fortress's depreciation expense for the three months ended September 30, 2016 and 2015 was approximately $ 154,000 6,000 Fortress's depreciation expense for the nine months ended September 30, 2016 and 2015 was approximately $ 240,000 17,000 September 9, Estimated Useful ($ in thousands) 2016 Lives (in years) Equipment $ 532 5 Furniture and fixtures 65 5 Leasehold improvements 259 Lesser of useful life or term of lease Capital Leases (primarily composed of computer equipment) 276 5 Property and equipment, net $ 1,132

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	7. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Laser Device for Treatment of Migraine Headache On March 17, 2014, the Company invested $ 250,000 35 13,409,962 83 16,091,954 250,000 Origo Acquisition Corporation (formerly CB Pharma Acquisition Corporation) On June 10, 2016 CB Pharma Acquisition Corp (“CB Pharma”) held an extraordinary general meeting of shareholders (the “Meeting”). At the Meeting, the shareholders approved each of the following items: (i) an amendment to the CB Pharma’s Amended and Restated Memorandum and Articles of Association (the “Charter”) to extend the date by which CB Pharma has to consummate a business combination from June 12, 2016 to December 12, 2016 (the “Extension”), (ii) an amendment to the Charter to allow the holders of the CB Pharma’s ordinary shares issued in the their initial public offering to elect to convert their shares into their pro rata portion of the funds held in trust, if the Extension is approved, and (iii) the change of CB Pharma’s name from “CB Pharma Acquisition Corp.” to “Origo Acquisition Corporation” (“Origo”). In connection with the Meeting, the Company transferred 1,050,000 265,000 As of September 30, 2016, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 31.89 5.04 25.6 1.14 11.50 0.50 0.13 31.89 1.61 0.16 0.04 1.8 which $ 25,000 1.775 0.4 31.7 0.3 NSC Contingently Issuable Warrant Pursuant to the Amended NSC Note (see Note 11), if a Fortress Company has the proceeds of the NSC Note transferred to it, such Fortress Company will issue a note to NSC and NSC will also receive a warrant to purchase a number of shares of the Fortress Company’s stock equal to 25 10 Derivatives and Hedging. Avenue classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Avenue’s $ 3.0 Mustang classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Mustang’s $ 3.6 September 30, 2016 Avenue Mustang Risk-free interest rate 1.60 % 1.60 % Expected dividend yield - % - % Expected term in years 9.09 9.76 Expected volatility 83.00 % 76.70 % Probability of issuance of the warrant 50.00 % 100.00 % Helocyte Warrant Liabilities The fair value of Helocyte’s warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. September 30, Risk-free interest rate 0.64 % Expected dividend yield - % Expected term in years 1.25-1.50 Expected volatility 60.0% - 63.3 % Strike price $ 0.15 Helocyte’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. September 30, Risk-free interest rate 0.64 % Expected dividend yield - % Expected term in years 1.25-1.50 Expected volatility 60.0% - 63.3 % Probability of conversion 0.15 Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 114 $ - $ - $ 114 Municipal bonds 1,550 - - 1,550 Restricted stock - 514 - 514 Fortress Long-term investments, at fair value - - 685 685 Total assets $ 1,664 $ 514 $ 685 $ 2,863 Liabilities Fortress Contingently issuable warrants $ - $ - $ 853 $ 853 Warrant liabilities - - 98 98 Helocyte convertible note, at fair value - - 3,031 3,031 Total liabilities $ - $ - $ 3,982 $ 3,982 Certain positions in common stock were received as compensation for investment banking services. Restricted common stock may be freely traded only upon the effectiveness of a registration statement covering them or upon the satisfaction of the requirements of Rule 144, including the requisite holding period. Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114 Helocyte Investment Securities Contingently Convertible Investment in laser owned, at Issuable Note, at fair Warrant ($ in thousands) in Origo device fair value Warrants value liabilities Total Balance at December 31, 2015 $ 2,235 $ 250 $ - $ 114 $ - $ - $ 2,599 Additions during the period - - 2,178 634 3,018 98 5,928 Change in fair value of investments (1,800) - - - - - (1,800) Change in fair value of convertible notes - - - - 13 - 13 Change in fair value of derivative liabilities - - - 105 - - 105 Balance at September 30, 2016 $ 435 $ 250 $ 2,178 $ 853 $ 3,031 $ 98 $ 6,845 Investment in Investment in ($ in thousands) Origo laser device Total Balance at December 31, 2014 $ 3,910 $ 250 $ 4,160 Change in fair value of investments (65) - (65) Balance at September 30, 2015 $ 3,845 $ 250 $ 4,095 For the nine months ended September 30, 2016 and 2015, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Licenses Acquired

Licenses Acquired	9 Months Ended
	Sep. 30, 2016
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development For the Three Months For the Nine Months Ended September 30, Ended September 30, ($ in thousands) 2016 2015 2016 2015 Fortress Companies: Avenue $ - $ - $ - $ 3,000 Checkpoint 1,000 600 3,060 2,633 Coronado SO - - - 1,607 Helocyte - - 83 200 Mustang - - - 2,147 Escala - 1,295 - 1,295 Total $ 1,000 $ 1,895 $ 3,143 $ 10,882 Avenue Therapeutics, Inc. License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to IV Tramadol for the U.S. market from Revogenex, a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 research and development-licenses acquired 1.0 The Company transferred the Revogenex license and all other rights and obligations of Fortress under the License Agreement to Avenue pursuant to the Avenue Founders Agreement effective as of February 17, 2015. Per the terms of the agreement, Avenue assumed $ 3.0 During the nine months ended September 30, 2016, Avenue completed a pharmacokinetics or PK study for IV Tramadol in healthy volunteers and completed an End-of-Phase 2 (EOP) meeting with the U.S. Food and Drug Administration (the “FDA”). Checkpoint Therapeutics, Inc. License Agreement with Dana-Farber Cancer Institute In March 2015, Checkpoint entered into an exclusive license agreement with Dana-Farber Cancer Institute (“Dana-Farber”) to develop a portfolio of fully human immuno-oncology targeted antibodies. The portfolio of antibodies licensed from Dana-Farber includes antibodies targeting PD-L1, GITR and CAIX. Under the terms of the agreement, Checkpoint paid Dana-Farber an up-front licensing fee of $ 1.0 500,000 32,500 0.065 5 10 136,830 0.6 21.5 60.0 In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies, while Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Executive Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, Interim President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the agreement, TGTX paid Checkpoint $ 0.5 21.5 7.0 14.5 60.0 0 25,000 20,000 0.5 NeuPharma, Inc. In March, 2015, the Company entered into an exclusive license agreement with NeuPharma, Inc. (“NeuPharma”) to develop and commercialize novel irreversible, 3rd generation epidermal growth factor receptor (“EGFR”) inhibitors including CK-101, on a worldwide basis (other than certain Asian countries). On the same date, the Company assigned all of its right and interest in the EGFR inhibitors to Checkpoint. Under the terms of the agreement, Checkpoint paid NeuPharma an up-front licensing fee of $ 1.0 40.0 22.5 40.0 In connection with the license agreement with NeuPharma, in March 2015, the Company entered into an option agreement with TGTX, a related party, which agreement was assigned to Checkpoint on the same date, for a global collaboration for the future development of certain licensed compounds in the field of hematological malignancies. The option was extended on July 8, 2016 for an additional 176 days, to December 31, 2016. Also in connection with the license agreement with NeuPharma, Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this agreement and reimbursed Checkpoint for costs previously paid by Checkpoint. The Company recognized approximately $ 251,000 732,000 Teva Pharmaceutical Industries Ltd. (through its subsidiary, Cephalon, Inc.) In December 2015, the Company entered into a license agreement with Teva Pharmaceutical Industries Ltd. through its subsidiary, Cephalon, Inc. (“Cephalon”), which agreement was assigned to Checkpoint by the Company on the same date. Under the terms of the license agreement, Checkpoint obtained an exclusive, worldwide license to Cephalon’s patents relating to CEP-8983 and its small molecule prodrug, CEP-9722, a PARP inhibitor, which Checkpoint now refers to as CK-102. Checkpoint paid Cephalon an up-front licensing fee of $ 0.5 220.0 206.5 Jubilant Biosys Limited In May 2016, Checkpoint entered into a License Agreement with Jubilant Biosys Limited (“Jubilant”), whereby Checkpoint obtained an exclusive, worldwide license (the “Jubilant License”) to Jubilant’s family of patents covering compounds that inhibit BRD4, a member of the BET domain for cancer treatment, which Checkpoint refers to as CK-103. Under the terms of the Jubilant License, Checkpoint paid Jubilant an up-front licensing fee of $ 2.0 89.0 59.5 89.0 2.0 research and development-licenses acquired In connection with the Jubilant License, Checkpoint entered into a sublicense agreement with TGTX (the “Sublicense Agreement”), a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, with Checkpoint retaining the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Executive Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, Interim President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the Sublicense Agreement, TGTX paid Checkpoint $ 1.0 87.5 0.3 25.5 61.7 89.0 50 0.3 1.3 Coronado SO Company License Agreement In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of hand-foot syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 10.7 26.2 The Company valued the stock grant to the third party utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 1.19 0.2 Helocyte, Inc. License Agreement with the City of Hope In March 2016, Helocyte entered into amended and restated license agreements for each of its PepVax and Triplex immunotherapies programs with its licensor City of Hope National Medical Center (“COH”). The amended and restated licenses expand the intellectual property and other rights granted to Helocyte by COH in the original license agreement. The financial terms of the original license have not been modified, and if Helocyte successfully develops and commercializes PepVax and Triplex, COH will receive milestones, royalties and other payments. Helocyte entered into the original license agreement with COH on March 31, 2015, to secure: (i) an exclusive worldwide license for two immunotherapies for CMV control in the post-transplant setting (known as Triplex and PepVax); and (ii) an option for an exclusive worldwide license to an immunotherapy for the prevention of congenital CMV (known as Pentamer). In consideration for the license and option, Helocyte made an upfront payment of $ 155,000 50,000 1.5 13.0 0.2 9.0 26.0 0.75 5.5 26.0 0.75 As further consideration for the licenses, in March and May 2016, Helocyte granted COH 500,000 8,333 44.5 30 0.097 48,500 License Option In February 2016, Helocyte entered into an option agreement for $ 35,000 35,000 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into an exclusive license agreement with COH to acquire intellectual property rights pertaining to CAR T. Pursuant to the agreement, Mustang paid COH an upfront fee of $ 2.0 research and development-licenses acquired expenses 1.0 10 2.0 14.5 1.0 The Company valued the stock grant to COH utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.147 0.1 Escala Therapeutics, Inc. On July 16, 2015, Escala acquired from New Zealand Pharmaceuticals Limited (“NZP”) a license from the National Institute of Health (“NIH”) and cooperative research and development agreements for the development of oral ManNAc, a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Escala provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 Seven milestones totaling approximately $22.6 million are due upon the achievement of certain development goals, two milestones totaling $7.0 million are due upon certain net sales milestones and a single digit royalty on net sales is due for a certain period. In addition, a one-time payment is due upon the termination of the license.

Milestones and Sponsored Resear

Milestones and Sponsored Research Agreements	9 Months Ended
	Sep. 30, 2016
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Milestones and Sponsored Research Agreements Helocyte In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“PepVax Arrangement”). The Phase 2 study is additionally supported by grants from the National Cancer Institute. Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 2.0 In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“Triplex Arrangement”). The Phase 2 study is additionally supported by grants from the National Cancer Institute. Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 3.4 In August 2016, Helocyte made a payment of $ 2 1 1 1.1 0.5 0.6 0.9 2.9 Mustang In March 2015, in connection with Mustang’s license with COH for the development of CAR T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 0.5 0.5 1.5 1.0 CNDO-109 The Company has a license agreement with the University College London Business PLC (“UCLB”) under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions. In consideration for the license, the Company made upfront payments totaling $ 0.1 22 0.4 3 5

Intangibles, net

Intangibles, net	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, net	10. Intangibles, net Journey Medical Corporation In January 2016, JMC entered into a licensing agreement to distribute its prescription wound cream Luxamend ® 50,000 TM 0.3 29,000 50,000 In March 2015, JMC entered into a license and supply agreement to acquire the rights to an oral antibiotic, for the treatment of severe acne. JMC made an upfront payment of $ 1.3

Debt and Interest

Debt and Interest	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt and Interest	11. Debt and Interest Debt September 30, December 31, ($ in thousands) 2016 2015 Interest rate Maturity IDB Note $ 14,929 $ 14,009 2.25 % Feb - 2018 NSC Note 7,208 10,000 8.00 % Mar - 2018 Helocyte Convertible Note, at fair value 3,031 — 5.00% -8.00 % Dec - 2017 Opus Credit Facility 5,000 — 12 % Sep - 2018 Total notes payable, long-term 30,168 24,009 Less: Discount on notes payable 2,764 835 Total notes payable, long-term, net $ 27,404 $ 23,174 IDB Note On February 13, 2014, the Company executed a promissory note in favor of IDB in the amount of $ 15.0 14 100,000 100,000 2.25 The obligations of the Company under the IDB Note are collateralized by a security interest in, a general lien upon, and a right of set-off against the Company’s money market account of $ 15.0 The Company will default on the IDB Note if, among other things, it fails to pay outstanding principal or interest when due. Following the occurrence of an event of default under the IDB Note, IDB may: (i) declare the entire outstanding principal balance of the IDB Note, together with all accrued interest and other sums due under the IDB Note, to be immediately due and payable; (ii) exercise its right of setoff against any money, funds, credits or other property of any nature in possession of, under control or custody of, or on deposit with IDB; (iii) terminate the commitments of IDB; and (iv) liquidate the money market account to reduce the Company’s obligations to IDB. Effective March 31, 2015, the Company and IDB extended the maturity date of the IDB Note to February 27, 2017. At September 30, 2016, the Company had approximately $ 14.9 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10 12 8 0.9 notes payable, long-term 12.4 The NSC Note was amended and restated on July 29, 2015 to provide that any time a Fortress subsidiary receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “Amended NSC Note”) on identical terms as the NSC Note, giving effect to the passage of time with respect to maturity. The Amended NSC Note will equal the dollar amount of the Fortress Company’s share of the NSC Note and reduce the Company’s obligations under the NSC Note by such amount. The Company will guarantee the Amended NSC Note until the Fortress Company either completes an initial public offering of its securities or raises sufficient equity capital so that it has cash equal to five times the Amended NSC Note. As of September 30, 2016, the Company transferred $ 2.8 3.6 10 In connection with the transfer of NSC Note proceeds to a Fortress Company, NSC has received, or will receive a warrant to purchase the Fortress Company’s stock equal to 25 10 As of September 30, 2016, Avenue recorded approximately $ 370,000 114,000 In February 2016, Checkpoint repaid its NSC Debt of $ 2.8 324,000 174,000 In July 2016, Fortress transferred $ 3.6 25 763,000 634,000 Helocyte Convertible Note On June 30, 2016, Helocyte held the first closing of the sale of convertible promissory notes. Helocyte sold eleven convertible promissory notes to investors for an aggregate of $1.0 million. The notes have an initial term of 18 5 8 10.0 10.0 On September 30, 2016, Helocyte realized net proceeds in two separate closings of $2.7 million after paying Aegis Capital Corp. (“Aegis”) its placement fee of $0.3 million, or approximately 10 301,800 100,000 201,800 110 5.0 Due to the complexity and number of embedded features within each convertible note, and as permitted under accounting guidance, the Company elected to account for the convertible notes and all the embedded features (collectively, the “hybrid instrument”) under the fair value option (see Note 7). Opus Credit Facility Agreement On September 14, 2016, Fortress entered into a Credit Facility Agreement (the “Opus Credit Facility”) with Opus Point Healthcare Innovations Fund, LP (“OPHIF”). Since Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael S. Weiss), are Co-Portfolio Managers and Partners of Opus Point Partners Management, LLC (“Opus”), an affiliate of OPHIF, all of the disinterested directors of Fortress’s board of directors approved the terms of the Credit Facility Agreement and accompanying Pledge and Security Agreement and forms of Note and Warrant (collectively, the “Financing Documents”). Pursuant to the Opus Credit Facility, Fortress may borrow up to a maximum aggregate amount of $ 25.0 Pursuant to the Opus Credit Facility and form of Note, each Note will bear interest at 12 Fortress may terminate the Opus Credit Facility upon notice to the Lenders and payment of all outstanding obligations under the Credit Facility Agreement. Notwithstanding any early termination of the Credit Facility Agreement, within 15 days after termination of the Commitment Period, Fortress will issue each Lender warrants (each a “Warrant”) pursuant to the terms of the Credit Facility Agreement and form of Warrant to purchase their pro rata share of (a) 1,500,000 3.00 As of September 30, 2016, $ 5.0 1.9 IDB Letters of Credit The Company has several letters of credit (“LOC”) with IDB securing rent deposits for lease facilities totaling approximately $ 1.5 2 For the Three Months For the Nine Months Ended September 30, Ended September 30, ($ in thousands) 2016 2015 2016 2015 IDB Note Interest $ 84 $ 82 $ 243 $ 235 Amortization of fees - 1 1 3 Total IDB Note 84 83 244 238 NSC Debt Interest 145 208 456 488 Amortization of fees 135 59 557 140 Total NSC Debt 280 267 1,013 628 Ovamed Interest - - - 167 Total Ovamed - - - 167 LOC Fees Interest 3 - 10 - Total LOC 3 - 10 - Helocyte Convertible Note Interest 26 - 26 - Financing fees 242 - 491 - Total Helocyte 268 - 517 - Opus Credit Facility Interest 26 - 26 - Amortization of Fees 28 - 28 - Total Opus 54 - 54 - Total Interest Expense $ 689 $ 350 $ 1,838 $ 1,033

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	12. Accrued Expenses and Other Long-Term Liabilities September 30, December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 1,389 $ 382 Salaries, bonuses and related benefits 1,777 2,492 Ovamed manufacturing rights - short term component 750 1,500 Research and development 788 810 Dr. Falk Pharma milestone 2,802 2,717 Accrued royalty and coupons 301 - Lease impairment 95 146 Other 703 523 Total accrued expenses $ 8,605 $ 8,570 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,583 584 Total other long-term liabilities $ 4,583 $ 584 September 9, ($ in thousands) 2016 Legal $ 961 Audit 196 Telecommunications 181 Data Services 229 Regulatory 365 Settlements 701 Deferred rent 39 Contingent consideration payable 423 Other 2,984 Total $ 6,079

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
	Sep. 30, 2016
Noncontrolling Interest [Abstract]
Non-Controlling Interests	13. Non-Controlling Interests As of September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte National Total NCI equity share $ (494) $ (217) $ 1,337 $ 33,004 $ (277) $ (531) $ 17,717 $ 50,539 Net loss attributed to non-controlling interests (231) (14) (363) (10,767) (333) (616) - (12,324) Non-controlling interests in consolidated entities $ (725) $ (231) $ 974 $ 22,237 $ (610) $ (1,147) $ 17,717 $ 38,215 As of December 31, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling interests in consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427 For the three months ended September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (47) $ (4) $ (204) $ (3,254) $ (104) $ (362) $ (3,975) Non-controlling ownership 10.5 % 13.0 % 23.9 % 62.7 % 8.1 % 20.6 % For the three months ended September 30, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (367) $ (7) $ (54) $ (977) $ (289) $ (1,694) Non-controlling ownership 11.5 % 13 % 10 % 20.0 % 25.0 % For the nine months ended September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (231) $ (14) $ (363) $ (10,767) $ (333) $ (616) $ (12,324) Non-controlling ownership 10.5 % 13.0 % 10.0 % 63.5 % 8.1 % 20.6 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares, which provide super-majority voting rights. For the nine months ended September 30, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (401) $ (237) $ (321) $ (1,168) $ (289) $ (2,416) Non-controlling ownership 11.5 % 13 % 10 % 20.0 % 25.0 %

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. Included in common stock issued and outstanding as of September 30, 2016 are 8,705,137 The Company’s common stock equivalents, including unvested restricted stock, options, and warrants that have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Warrants to purchase Common Stock 392,731 685,061 480,559 685,061 Opus warrants to purchase Common Stock 1,700,000 - 1,700,000 - Options to purchase Common Stock 1,761,032 1,832,499 1,769,426 2,019,219 Unvested Restricted Stock 8,705,136 6,884,631 8,763,797 6,795,132 Unvested Restricted Stock Units 1,085,468 752,761 1,054,091 258,242 Total 13,644,367 10,154,952 13,767,873 9,757,654

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	15. Stockholders’ Equity Stock-based Compensation excluding National As of September 30, 2016, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan and the Fortress Biotech. Inc. Long Term Incentive Plan (“LTIP”). Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2016 2015 2016 2015 Employee awards $ 1,937 $ 3,296 $ 5,490 $ 6,284 Executive awards of Fortress Companies' stock - 2,229 - 2,229 Non-employee awards 3 10 9 24 Fortress Companies (1) 963 2,966 3,293 3,359 Total stock-based compensation expense $ 2,903 $ 8,501 $ 8,792 $ 11,896 (1) Consists of approximately $ 5,000 0.8 130,000 67,000 23,000 2.7 458,000 160,000 Consists of approximately $ 15,000 2.1 279,000 38,000 2.1 279,000 147,000 In February 2016, the Company modified the vesting schedule on the 1.9 3.9 0.4 Number of shares Weighted average Total weighted Weighted average Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Granted - - - - Forfeited (648,864) 0.51 - - Options vested and expected to vest at September 30, 2016 1,130,501 $ 3.73 $ 745,069 5.18 Options vested and exercisable 1,065,501 $ 3.77 $ 710,269 5.08 As of September 30, 2016, the Company had unrecognized stock-based compensation expense related to unvested option of $ 16,000 0.22 Number of shares Weighted average Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 526,000 2.92 Restricted stock units cancelled (101,750) 3.64 Restricted stock units vested (223,375) 3.56 Unvested balance at September 30, 2016 9,993,012 $ 2.49 As of September 30, 2016, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $ 5.6 1.2 2.2 1.4 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 As of September 30, 2016, 125,150 74,850 13,000 56,000 28,000 33,958 81,000 Warrants Number of shares Weighted average Total weighted Weighted average Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,800,000 3.00 - 5.89 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 40,000 - Outstanding as of September 30, 2016 2,183,453 $ 3.64 $ 96,000 5.17 Exercisable as of September 30, 2016 383,453 $ 6.63 $ 96,000 1.79 (*) - cashless All stock-based expense in connection with these warrants has been recognized prior to January 1, 2016. Long-Term Incentive Program (“LTIP”) On July 15, 2015, the stockholders approved the LTIP for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss. The LTIP consists of a program to grant equity interests in the Company and in the Company’s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. On July 15, 2015, grants of 500,000 44.8 30 2.2 On January 1, 2016, the Compensation Committee granted 510,434 1 100,000,000 market condition , Compensation - Stock Compensation, 2.4 75,000 0.2 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint has a long-term incentive plan. In March 2015, Checkpoint issued a restricted stock grant to Dr. Marasco for services in connection with its Scientific Advisory Board. Dr. Marasco was issued a grant for 1.5 48 44.8 30 0.065 4.39 83 1.5 4.42 83 1.35 0.4 1.6 2.1 Certain employees and directors of Checkpoint have been awarded restricted stock under Checkpoint’s 2015 Incentive Plan. For the three and nine months ended September 30, 2016, the Company recorded stock-based compensation expense of approximately $ 0.3 1.0 20,000 Avenue Therapeutics, Inc. Avenue has a long term incentive program. During 2015, Avenue granted 1.0 44.8 30 0.146 50 12.5 50 2,500 11,500 13,000 16,000 For the three and nine months ended September 30, 2015, stock-based compensation expenses associated with the amortization of Avenue’s restricted stock award for non-employees were $ 0 22,000 Journey Medical Corporation During the nine months ended September 30, 2016, JMC granted 310,000 44.2 25.1 0.53 0 For the nine Risk-free interest rate 1.14%- 1.82 % Expected dividend yield - Expected term in years 5.11-6.95 Expected volatility 95.25% - 104.76 % During the three and nine months ended September 30, 2016, stock-based compensation associated with the amortization of stock option expense was approximately $ 0.1 0.4 29,000 95,000 279,000 Helocyte, Inc. On March 30, 2016, Helocyte granted 150,000 508,333 127,084 0.46 68 1.3 50,000 118,000 On March 30, 2016, Helocyte granted 1.0 0.097 17,000 42,000 Capital Raise Checkpoint On February 23, 2016, Checkpoint closed on proceeds of $ 0.6 10,000 3,500 7.00 45,000 126,640 44,324 As of September 30, 2016, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. Mustang On September 30, 2016, Mustang closed on gross proceeds of $ 12.4 1.2 10 10,000 2,500 8.50 65,000 1.9 478,708 191,483 10 As of September 30, 2016, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. Amendment and Restatement of At Market Issuance Sales Agreement On August 17, 2016, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or Sales Agreement, with MLV & Co, or MLV, and FBR Capital Markets & Co., or FBR. On August 18, 2016, the Company filed a Registration Statement on Form S-3 which, upon effectiveness, will permit the Company to issue and sell shares of its common stock having an aggregate offering price of up to $ 53.0

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Operating Lease Obligations - National ($ in thousands) Fiscal Year Rental Less, Net 2017 $ 3,015 $ 84 $ 2,931 2018 2,253 - 2,253 2019 1,462 - 1,462 2020 1,298 - 1,298 2021 1,004 - 1,004 Thereafter 2,062 - 2,062 Total $ 11,094 $ 84 $ 11,010 As of September 9, 2016, National had outstanding one letter of credit, which has been issued in the maximum amount of $ 194,000 Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions. Legal Proceedings - Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. Litigation and Regulatory Matters - National National is a defendant or respondent in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its brokers that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where management believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect management’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters. These amounts are included in accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Awards ultimately paid, if any, may be covered by their errors and omissions insurance policy. While National will vigorously defend itself in these matters, and will assert insurance coverage and indemnification to the maximum extent possible, there can be no assurance that such matters will not have a material adverse impact on its financial position, results of operations or cash flows.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Note	17. Related Party Transactions Services Agreement with Opus Point Management Partners, LLC On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately $ 0 66,000 84,000 154,000 Shared Services Agreement with TGTX In July 2015, TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three and nine months ended September 30, 2016, the Company invoiced TGTX $ 0.3 0.6 71,800 Desk Space Agreements with TGTX and OPPM In September 2014, the Company entered into Desk Space Agreements with OPPM and TGTX to occupy 20 40 0.5 1.1 45 10 Each initial Desk Space Agreement has a term of five years. The Company took possession of the New York, NY office space in December 2015, commenced build out of the space shortly thereafter and took occupancy of the space in April 2016. The Company expects the total build out costs to approximate $ 5.1 0.4 37,000 180,000 4.7 2.6 0.6 Checkpoint Agreements with TGTX Checkpoint has entered into various agreements with TGTX to develop and commercialize certain assets in connection with its licenses, including a collaboration agreement for some of the Dana Farber licensed antibodies, an option agreement and sponsored research agreement for the NeuPharma EGFR inhibitor, and a sublicense agreement for the Jubilant BET inhibitor. Checkpoint believes that by partnering with TGTX to develop these compounds in therapeutic areas outside of its business focus, it may substantially offset its preclinical costs and milestone costs related to the development and marketing of these compounds in solid tumor indications. Opus Credit Facility On September 14, 2016, Fortress entered the Opus Credit Facility with OPHIF. Since Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael S. Weiss), are Co-Portfolio Managers and Partners of Opus, an affiliate of OPHIF, all of the disinterested directors of Fortress’s board of directors approved the terms of the Credit Facility Agreement and accompanying Pledge and Security Agreement and forms of Note and Warrant (see Note11). Founders Agreement and Management Services Agreement with Checkpoint Effective March 17, 2015, the Company entered into a Founders Agreement with Checkpoint, which was amended and restated on July 11, 2016 (the “Checkpoint Founders Agreement”). The Checkpoint Founders Agreement provides that, in exchange for the time and capital expended in the formation of Checkpoint and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Checkpoint assumed $ 2.8 Effective March 17, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Checkpoint. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Checkpoint. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Checkpoint’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Checkpoint with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Checkpoint is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by the Company, provided those services are offered at market prices. However, Checkpoint is not obligated to take or act upon any advice rendered from the Company and the Company shall not be liable for any of Checkpoint’s actions or inactions based upon the Company’s advice. Fortress and its affiliates, including all members of the Checkpoint’s Board of Directors, have been contractually exempt from fiduciary duties to Checkpoint relating to corporate opportunities. In consideration for the Services, Checkpoint will pay the Company an annual consulting fee of $ 0.5 1.0 100 Founders Agreement and Management Services Agreement with Avenue Effective as of February 17, 2015, the Company entered into a Founders Agreement with Avenue, which was amended and restated on September 13, 2016 (the “Avenue Founders Agreement”), pursuant to which the Company assigned to Avenue all of its rights and interest under the Company’s license agreement with Revogenex for IV Tramadol. As consideration for the Avenue Founders Agreement, Avenue assumed $ 3.0 the Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class A Common shares for approximately 7.5 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights, election of directors and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Avenue common stock and (B) the whole shares of Avenue common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Avenue common stock, subject to certain adjustments. For a period of 10 years from the date of the first issuance of Class A Preferred Stock, the holders of record of shares of Class A Preferred Stock, exclusively and as a separate class, are entitled to appoint or elect the majority of Avenue’s Board of Directors. As holders of Class A Preferred Stock, the Company will receive on each February 17 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Avenue’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. Effective as of February 17, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Avenue and each of Avenue’s current directors and officers who are directors or officers of the Company to provide services to Avenue pursuant to the terms of the MSA. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Avenue. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Avenue’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Avenue with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Avenue is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Avenue is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Avenue’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Avenue’s Board of Directors, have been contractually exempt from fiduciary duties to Avenue relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $ 0.5 1.0 100 Founders Agreement and Management Services Agreement with Helocyte Effective March 20, 2015, the Company entered into a Founders Agreement with Helocyte, which was amended and restated as of September 14, 2016 (the “Helocyte Founders Agreement”), pursuant to which the Company agreed to provide the initial funding required by the COH License Agreement for PepVax and Triplex, as well as other operating capital needed to meet Helocyte’s initial capital requirements. As consideration for the Helocyte Founders Agreement, upon Helocyte commencing a third party financing, Helocyte will assume the Company’s accumulated debt, attributable to Helocyte’s expenses and costs associated with its formation, license acquisition and expenses, under the NSC Note (“NSC Note”), or other similar debt. The Helocyte Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Helocyte Founders Agreement) occurs. Concurrently with the amendment and restatement of the Helocyte Founders Agreement, the Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class B Common shares for 6.75 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Helocyte common stock and (B) the whole shares of Helocyte common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Helocyte common stock, subject to certain adjustments. As the sole holder of Class A Preferred Stock, the Company will receive on each March 20 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Helocyte’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. Effective March 20, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Helocyte and each of Helocyte’s current directors and officers who are directors or officers of the Company to provide services to Helocyte pursuant to the terms of the MSA. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Helocyte. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Helocyte’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Helocyte with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Helocyte is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Helocyte is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Helocyte’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Helocyte’s Board of Directors, have been contractually exempt from fiduciary duties to Helocyte relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $ 0.5 1.0 100 Founders Agreement and Management Services Agreement with Mustang Effective March 13, 2015, the Company entered a Founders Agreement with Mustang, which was amended and restated on May 17, 2016 and again on July 26, 2016 (the “Mustang Founders Agreement”). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, the Company will loan 2.0 15 As additional consideration under the Mustang Founders Agreement, Mustang will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). Effective as of March 13, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Mustang. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Mustang. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Mustang’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Mustang with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Mustang is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Mustang is not obligated to take or act upon any advice rendered from Fortress, and Fortress shall not be liable for any of Mustang’s actions or inactions based upon Fortress’s advice. Fortress and its affiliates, including all members of Mustang’s Board of Directors, have been contractually exempt from fiduciary duties to Mustang relating to corporate opportunities. In consideration for the Services, Mustang will pay Fortress an annual consulting fee of $ 0.5 1.0 100 As consideration for the Mustang Founders Agreement, Mustang assumed $ 3.6 Chord Advisors, LLC In May 2015, the Company entered into a full service consulting agreement with Chord Advisors, LLC (“Chord”) to provide advisory accounting services. Under the terms of the agreement, the Company pays Chord $ 10,000 5,000 7,500 National In September 2016, pursuant to the terms of the Merger Agreement between National and Fortress, the Company acquired 56.1 22.9 1.3 Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM which owns approximately 4.6

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	9 Months Ended
	Sep. 30, 2016
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	18. Net Capital Requirements of Broker-Dealer Subsidiaries National Securities is subject to the Securities and Exchange Commission Uniform Net Capital Rule (Rule 15c3-1) (the Rule), which, among other things, requires the maintenance of minimum net capital. In February 2015, pursuant to a directive from FINRA, National Securities reverted back to using the alternative method of computing net capital from the aggregate indebtedness method. At September 9, 2016, National Securities had net capital of $ 5.6 5.4 250,000 vFinance Investments is also subject to the Rule, which, among other things, requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. At September 9, 2016, vFinance Investments had net capital of $ 2.2 1.2 1.0 was 77.9 Advances, dividend payments and other equity withdrawals from its Broker-Dealer Subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure	19. Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure	20. Segment Information The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue, which made up all of the Dermatology Product Sales in the first quarter had no cost of goods sold. As a result, cost of goods sold was only recorded in the three months ended September 30, 2016. Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Three Months Ended September 30, 2016 Sales Development National Consolidated Net Revenue $ 429 $ 546 $ - $ 975 Direct cost of goods (41) - - (41) Sales and marketing costs (1,244) - - (1,244) Research and development - (8,316) - (8,316) General and administrative (422) (7,198) - (7,620) Segment loss from operations $ (1,278) $ (14,968) $ - $ (16,246) Segment assets $ 2,657 $ 103,225 $ 39,539 $ 145,421 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Three Months Ended September 30, 2015 Sales Development Consolidated Net Revenue $ - $ 25 $ 25 Sales and marketing costs (950) - (950) Research and development - (10,968) (10,968) General and administrative (516) (5,663) (6,179) Segment loss from operations $ (1,466) $ (16,606) $ (18,072) Segment assets $ 1,593 $ 85,271 $ 86,864 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Nine Months Ended September 30, 2016 Sales Product Development National Consolidated Net Revenue $ 1,793 $ 2,072 $ - $ 3,865 Direct cost of goods (365) - - (365) Sales and marketing costs (4,212) - - (4,212) Research and development - (24,559) - (24,559) General and administrative (1,338) (19,864) - (21,202) Segment loss from operations $ (4,122) $ (42,351) $ - $ (46,473) Segment assets $ 2,657 $ 103,225 $ 39,539 $ 145,421 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Nine Months Ended September 30, 2015 Sales Development Consolidated Net Revenue $ - $ 525 $ 525 Direct cost of goods - - $ - Sales and marketing costs (1,632) - (1,632) Research and development - (24,054) (24,054) General and administrative (1,134) (11,610) (12,744) Segment loss from operations $ (2,766) $ (35,139) $ (37,905) Segment assets $ 1,593 $ 85,271 $ 86,864 Significant Customers For the three months ended September 30, 2016, two of the Company’s customers accounted for more than 10.0% of its total revenue in the amount of $ 0.2 43,000 0.8 0.3 0.3 At September 30, 2016, three of the Company’s customers accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 0.1 71,000 50,000 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events Mustang On October 25, 2016 Mustang closed an additional round of financing totaling gross proceeds of $ 7.1 0.7 10 10,000 2,500 8.50 65,000 1.1 272,645 109,058 10 Pursuant to the terms of Mustang’s $ 3.6 138,462 Helocyte On October 31, 2016 Helocyte closed its third round of financing in connection with its convertible debt and raised gross proceeds of $ 1.0 0.1 Cellvation On October 31, 2016 Cellvation entered into two Patent & Technology License Agreements with The University of Texas Health Science Center at Houston (“UTHealth”) for a combined upfront fee of $ 300,000 5

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 15, 2016, from which the Company derived the balance sheet data at December 31, 2015 as well as National’s Form 10-K, which was filed with the SEC on December 28, 2015, Checkpoint’s Form 10G/A, filed with the SEC on August 19, 2016, and Mustang’s Form 10G/A, filed with the SEC on October 18, 2016. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte and Cellvation, Inc. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The National assets acquired and liabilities assumed as of September 9, 2016 are based upon estimated assets and liabilities as of September 9, 2016. The Company did not include revenues or expenses from the period from September 9, 2016 to September 30, 2016 as such amounts would be immaterial to the unaudited condensed consolidated financial statements. The Company believes National’s assets acquired and liabilities assumed as of September 9, 2016 approximate such balances as of September 30, 2016.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurement	The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires that fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the Company’s sublicense agreement with Ovamed has been recorded at its net present value, which approximates its fair value. The amounts due to Ovamed are included in current liabilities at September 30, 2016 and at December 31, 2015 on the Condensed Consolidated Balance Sheets (see Note 12). On August 1, 2016, the Company entered into a Settlement and Forbearance Agreement with Ovamed to settle contractual obligations of approximately $ 1.9 1.1 0.8 .
Segment Reporting	Consistent with the increase in JMC’s operations as of April 1, 2016 and the investment in NHLD as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. There are no significant inter-segment sales. The Company evaluates the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.
Property and Equipment	Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows.
Restricted Cash	Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of September 30, 2016, the Company has $ 15.5 14.9 0.6
Inventories	Inventories Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand.
Accounts Receivable	Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for doubtful accounts of $ 0
Investments at Fair Value	Investments at Fair Value The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument-by-instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments in the Condensed Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Fair Value Option	Fair Value Option As permitted under the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 825, Financial Instruments,
Accounting for Warrants at Fair Value	Accounting for Warrants at Fair Value The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants (the “Helocyte Warrants”) issued, in connection with the Helocyte convertible note financing in June 2016 and September 2016, and determined that the Helocyte Warrants met the criteria for liability classification. Accordingly, the Company classified the Helocyte Warrants as a liability at their fair value and adjusts the instruments to fair value at each balance sheet date until the warrants are exercised or expired. Any change in the fair value of the Helocyte Warrants is recognized as “change in the fair value of warrant liabilities” in the Condensed Consolidated Statements
Credit Facility With Detachable Warrant	The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the effective interest rate of the 39.49 Derivatives and Hedging
Issuance of Debt and Equity	Issuance of Debt and Equity The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt
Valuation of Warrants Related to NSC Note	Valuation of Warrants Related to NSC Note In accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the NSC Note transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants (see Note 7 and Note 11). At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date would be recognized as a change in fair value of derivative liabilities in the Condensed Consolidated Statements of Operations.
Recognizing Assets Acquired And Liabilities Assumed In A Business Combination, Policy	Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets.
Goodwill and Intangible Assets, Policy	Goodwill, Intangible Assets and Long Lived Assets Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit's goodwill to the carrying value of the reporting unit's goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The methodologies the Company utilizes in estimating the fair value of reporting units include market valuation methods that incorporate price-to-earnings and price-to-book multiples of comparable exchange traded companies and multiples of merger and acquisitions of similar businesses. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Deferred Financing Costs	Deferred Financing Costs Financing costs incurred in connection with the promissory note for $ 15.0
Revenue Recognition	Revenue Recognition The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Reimbursement Arrangements and Collaborative Arrangements Checkpoint is reimbursed by TG Therapeutics, Inc. (“TGTX”), a related party, for TGTX’s share of the cost of the license and product research and development under their collaboration and sublicense agreements. The gross amount of these reimbursed costs is reported as revenue in the Condensed Consolidated Statements of Operations, since the Company acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45, Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Condensed Consolidated Balance Sheets and recognized as revenue in the Condensed Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition - Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 13).
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Recently Issued Accounting Standards	Recent Accounting Pronouncements In January 2016, FASB issued Accounting Standards Update (“ASU”) No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU No. 2016-09”) In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customer (“ASU No. 2016-10”) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,
National [Member]
Revenue Recognition	Revenue Recognition Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients' investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National's principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National's share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers’ assets under management, may be billed monthly or quarterly and are recognized as earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services.
Consolidation, Policy	Principals of Consolidation The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
Securities Owned Not Readily Marketable, Policy	Securities Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. See Note 7 for fair value and classification of securities.
Deferred clearing And marketing Credit	Deferred Clearing and Marketing Credits Deferred clearing credit represents a clearing fee rebate from National Financial Services (“NFS”), one of National’s clearing brokers, which is being recognized pro rata as a reduction of clearing charges over the term of the clearing agreement which expires in 2022. At September 9, 2016, the deferred credit amounted to $ 687,000 Deferred marketing credit represents a marketing rebate from NFS, which is being recognized pro rata as a reduction of marketing expenses over the term of the clearing agreement which expires in 2022. At September 9, 2016, the deferred credit amounted to $ 321,000
Reimbursement Of Expenses	Reimbursement of Expenses National incurs certain costs on behalf of its financial advisors including those for insurance, professional registration, technology and information services and legal services, amongst others, which are charged back to the advisors. It is National’s policy to record the reimbursement as a reduction of the respective operating expense.
Legal Costs, Policy	In the normal course of business, National has been named, from time to time, as a defendant in legal and regulatory proceedings. National is also involved, from time to time, in other exams, investigations and similar reviews (both formal and informal) by governmental and self-regulatory agencies regarding its businesses, certain of which may result in judgments, settlements, fines, penalties or other injunctions. National recognizes a liability for a contingency in accrued expenses and other liabilities when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company accrues the most likely amount of such loss, and if such amount is not determinable, then the Company accrues the minimum in the range as the loss accrual. The determination of the outcome and loss estimates requires significant judgment on the part of management. National believes that any other matters for which it has determined a loss to be probable and reasonably estimable are not material to the condensed consolidated financial statements. In many instances, it is not possible to determine whether any loss is probable or even possible or to estimate the amount of any loss or the size of any range of loss. National believes that, in the aggregate, the pending legal actions or regulatory proceedings and any other exams, investigations or similar reviews (both formal and informal) should not have a material adverse effect on the consolidated results of operations, cash flows or financial condition

National Holdings Corporation (

National Holdings Corporation (Tables)	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Schedule fair value of assets acquired and liabilities assumed at the date of the acquisition	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed at the date of the acquisition: ($ in thousands) Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Goodwill 21,739 Total assets 62,411 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Other current liabilities 707 Total liabilities assumed 21,822 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626
Schedule of pro forma financial data assumes the acquisition	The impact of these items could alter the following pro forma results: Three Months Ended September 30, ($ in thousands) 2016 2015 Total revenues $ 47,317 $ 42,360 Net loss attributable to common stockholders (12,962) (17,797) Loss per share: Basic $ (0.32) $ (0.45) Diluted $ (0.32) $ (0.45) Nine Months Ended September 30, ($ in thousands) 2016 2015 Total revenues $ 131,862 $ 126,976 Net loss attributable to common stockholders (37,355) (34,985) Loss per share: Basic $ (0.94) $ (0.90) Diluted $ (0.94) $ (0.90)

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Line Items]
Components of Property and Equipment	Fortress's property and equipment, exclusive of National's property and equipment consisted of the following: September 30, December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 436 $ 13 Furniture and fixtures 5 788 69 Leasehold improvements 5 164 21 Construction in progress (1) 15 4,733 274 Total property and equipment 6,121 377 Less: Accumulated depreciation (296) (68) Property and equipment, net $ 5,825 $ 309 (1) For build-out of the Company's new office in New York, NY.
National Holdings Corporation [Member]
Property Plant And Equipment [Line Items]
Components of Property and Equipment	National’s preliminary property and equipment, at fair value as of September 9, 2016 consisted of the following: September 9, Estimated Useful ($ in thousands) 2016 Lives (in years) Equipment $ 532 5 Furniture and fixtures 65 5 Leasehold improvements 259 Lesser of useful life or term of lease Capital Leases (primarily composed of computer equipment) 276 5 Property and equipment, net $ 1,132

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis on the Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015: Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 114 $ - $ - $ 114 Municipal bonds 1,550 - - 1,550 Restricted stock - 514 - 514 Fortress Long-term investments, at fair value - - 685 685 Total assets $ 1,664 $ 514 $ 685 $ 2,863 Liabilities Fortress Contingently issuable warrants $ - $ - $ 853 $ 853 Warrant liabilities - - 98 98 Helocyte convertible note, at fair value - - 3,031 3,031 Total liabilities $ - $ - $ 3,982 $ 3,982 Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114
Schedule of changes in fair value of financial instruments	The table below provides a rollforward of the changes in fair value of Level 3 financial instruments for the nine months ended September 30, 2016 and 2015: Helocyte Investment Securities Contingently Convertible Investment in laser owned, at Issuable Note, at fair Warrant ($ in thousands) in Origo device fair value Warrants value liabilities Total Balance at December 31, 2015 $ 2,235 $ 250 $ - $ 114 $ - $ - $ 2,599 Additions during the period - - 2,178 634 3,018 98 5,928 Change in fair value of investments (1,800) - - - - - (1,800) Change in fair value of convertible notes - - - - 13 - 13 Change in fair value of derivative liabilities - - - 105 - - 105 Balance at September 30, 2016 $ 435 $ 250 $ 2,178 $ 853 $ 3,031 $ 98 $ 6,845 Investment in Investment in ($ in thousands) Origo laser device Total Balance at December 31, 2014 $ 3,910 $ 250 $ 4,160 Change in fair value of investments (65) - (65) Balance at September 30, 2015 $ 3,845 $ 250 $ 4,095
Avenue [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Avenue’s and Mustang’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option pricing model, with the following key assumptions: September 30, 2016 Avenue Mustang Risk-free interest rate 1.60 % 1.60 % Expected dividend yield - % - % Expected term in years 9.09 9.76 Expected volatility 83.00 % 76.70 % Probability of issuance of the warrant 50.00 % 100.00 %
Helocyte [Member] | Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	At September 30, 2016, the fair value equaled the proceeds received. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the convertible debt that is categorized within Level 3 of the fair value hierarchy for the three and nine months ended September 30, 2016 is as follows: September 30, Risk-free interest rate 0.64 % Expected dividend yield - % Expected term in years 1.25-1.50 Expected volatility 60.0% - 63.3 % Probability of conversion 0.15
Helocyte [Member] | Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the three and nine months ended September 30, 2016 is as follows: September 30, Risk-free interest rate 0.64 % Expected dividend yield - % Expected term in years 1.25-1.50 Expected volatility 60.0% - 63.3 % Strike price $ 0.15

Licenses Acquired (Tables)

Licenses Acquired (Tables)	9 Months Ended
	Sep. 30, 2016
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	For the three and nine months ended September 30, 2016 and 2015, the Company’s research and development-licenses acquired comprise of the following: For the Three Months For the Nine Months Ended September 30, Ended September 30, ($ in thousands) 2016 2015 2016 2015 Fortress Companies: Avenue $ - $ - $ - $ 3,000 Checkpoint 1,000 600 3,060 2,633 Coronado SO - - - 1,607 Helocyte - - 83 200 Mustang - - - 2,147 Escala - 1,295 - 1,295 Total $ 1,000 $ 1,895 $ 3,143 $ 10,882

Debt and Interest (Tables)

Debt and Interest (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Long-term debt to IDB, NSC and Helocyte consists of the following as of September 30, 2016 and December 31, 2015: September 30, December 31, ($ in thousands) 2016 2015 Interest rate Maturity IDB Note $ 14,929 $ 14,009 2.25 % Feb - 2018 NSC Note 7,208 10,000 8.00 % Mar - 2018 Helocyte Convertible Note, at fair value 3,031 — 5.00% -8.00 % Dec - 2017 Opus Credit Facility 5,000 — 12 % Sep - 2018 Total notes payable, long-term 30,168 24,009 Less: Discount on notes payable 2,764 835 Total notes payable, long-term, net $ 27,404 $ 23,174
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan: For the Three Months For the Nine Months Ended September 30, Ended September 30, ($ in thousands) 2016 2015 2016 2015 IDB Note Interest $ 84 $ 82 $ 243 $ 235 Amortization of fees - 1 1 3 Total IDB Note 84 83 244 238 NSC Debt Interest 145 208 456 488 Amortization of fees 135 59 557 140 Total NSC Debt 280 267 1,013 628 Ovamed Interest - - - 167 Total Ovamed - - - 167 LOC Fees Interest 3 - 10 - Total LOC 3 - 10 - Helocyte Convertible Note Interest 26 - 26 - Financing fees 242 - 491 - Total Helocyte 268 - 517 - Opus Credit Facility Interest 26 - 26 - Amortization of Fees 28 - 28 - Total Opus 54 - 54 - Total Interest Expense $ 689 $ 350 $ 1,838 $ 1,033

Accrued Expenses and Other Lo34

Accrued Expenses and Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Accounts Payable and Accrued Liabilities	September 30, December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 1,389 $ 382 Salaries, bonuses and related benefits 1,777 2,492 Ovamed manufacturing rights - short term component 750 1,500 Research and development 788 810 Dr. Falk Pharma milestone 2,802 2,717 Accrued royalty and coupons 301 - Lease impairment 95 146 Other 703 523 Total accrued expenses $ 8,605 $ 8,570 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,583 584 Total other long-term liabilities $ 4,583 $ 584
National Holdings Corporation [Member]
Schedule of Accounts Payable and Accrued Liabilities	September 9, ($ in thousands) 2016 Legal $ 961 Audit 196 Telecommunications 181 Data Services 229 Regulatory 365 Settlements 701 Deferred rent 39 Contingent consideration payable 423 Other 2,984 Total $ 6,079

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2016
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: As of September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte National Total NCI equity share $ (494) $ (217) $ 1,337 $ 33,004 $ (277) $ (531) $ 17,717 $ 50,539 Net loss attributed to non-controlling interests (231) (14) (363) (10,767) (333) (616) - (12,324) Non-controlling interests in consolidated entities $ (725) $ (231) $ 974 $ 22,237 $ (610) $ (1,147) $ 17,717 $ 38,215 As of December 31, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling interests in consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	The components of non-controlling interests in loss of consolidated entities are as follows: For the three months ended September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (47) $ (4) $ (204) $ (3,254) $ (104) $ (362) $ (3,975) Non-controlling ownership 10.5 % 13.0 % 23.9 % 62.7 % 8.1 % 20.6 % For the three months ended September 30, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (367) $ (7) $ (54) $ (977) $ (289) $ (1,694) Non-controlling ownership 11.5 % 13 % 10 % 20.0 % 25.0 % For the nine months ended September 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (231) $ (14) $ (363) $ (10,767) $ (333) $ (616) $ (12,324) Non-controlling ownership 10.5 % 13.0 % 10.0 % 63.5 % 8.1 % 20.6 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares, which provide super-majority voting rights. For the nine months ended September 30, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total Non-controlling interests in loss of consolidated entities $ (401) $ (237) $ (321) $ (1,168) $ (289) $ (2,416) Non-controlling ownership 11.5 % 13 % 10 % 20.0 % 25.0 %

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the nine months ended September 30, 2016 and 2015: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Warrants to purchase Common Stock 392,731 685,061 480,559 685,061 Opus warrants to purchase Common Stock 1,700,000 - 1,700,000 - Options to purchase Common Stock 1,761,032 1,832,499 1,769,426 2,019,219 Unvested Restricted Stock 8,705,136 6,884,631 8,763,797 6,795,132 Unvested Restricted Stock Units 1,085,468 752,761 1,054,091 258,242 Total 13,644,367 10,154,952 13,767,873 9,757,654

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2016 2015 2016 2015 Employee awards $ 1,937 $ 3,296 $ 5,490 $ 6,284 Executive awards of Fortress Companies' stock - 2,229 - 2,229 Non-employee awards 3 10 9 24 Fortress Companies (1) 963 2,966 3,293 3,359 Total stock-based compensation expense $ 2,903 $ 8,501 $ 8,792 $ 11,896 (1) Consists of approximately $ 5,000 0.8 130,000 67,000 23,000 2.7 458,000 160,000 Consists of approximately $ 15,000 2.1 279,000 38,000 2.1 279,000 147,000
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Number of shares Weighted average Total weighted Weighted average Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Granted - - - - Forfeited (648,864) 0.51 - - Options vested and expected to vest at September 30, 2016 1,130,501 $ 3.73 $ 745,069 5.18 Options vested and exercisable 1,065,501 $ 3.77 $ 710,269 5.08
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’ restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies (which is discussed below): Number of shares Weighted average Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 526,000 2.92 Restricted stock units cancelled (101,750) 3.64 Restricted stock units vested (223,375) 3.56 Unvested balance at September 30, 2016 9,993,012 $ 2.49
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Number of shares Weighted average Total weighted Weighted average Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,800,000 3.00 - 5.89 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 40,000 - Outstanding as of September 30, 2016 2,183,453 $ 3.64 $ 96,000 5.17 Exercisable as of September 30, 2016 383,453 $ 6.63 $ 96,000 1.79 (*) - cashless
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of options granted in 2016 was estimated using the following assumptions: For the nine Risk-free interest rate 1.14%- 1.82 % Expected dividend yield - Expected term in years 5.11-6.95 Expected volatility 95.25% - 104.76 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	($ in thousands) Fiscal Year Rental Less, Net 2017 $ 3,015 $ 84 $ 2,931 2018 2,253 - 2,253 2019 1,462 - 1,462 2020 1,298 - 1,298 2021 1,004 - 1,004 Thereafter 2,062 - 2,062 Total $ 11,094 $ 84 $ 11,010

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue, which made up all of the Dermatology Product Sales in the first quarter had no cost of goods sold. As a result, cost of goods sold was only recorded in the three months ended September 30, 2016. Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Three Months Ended September 30, 2016 Sales Development National Consolidated Net Revenue $ 429 $ 546 $ - $ 975 Direct cost of goods (41) - - (41) Sales and marketing costs (1,244) - - (1,244) Research and development - (8,316) - (8,316) General and administrative (422) (7,198) - (7,620) Segment loss from operations $ (1,278) $ (14,968) $ - $ (16,246) Segment assets $ 2,657 $ 103,225 $ 39,539 $ 145,421 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Three Months Ended September 30, 2015 Sales Development Consolidated Net Revenue $ - $ 25 $ 25 Sales and marketing costs (950) - (950) Research and development - (10,968) (10,968) General and administrative (516) (5,663) (6,179) Segment loss from operations $ (1,466) $ (16,606) $ (18,072) Segment assets $ 1,593 $ 85,271 $ 86,864 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Nine Months Ended September 30, 2016 Sales Product Development National Consolidated Net Revenue $ 1,793 $ 2,072 $ - $ 3,865 Direct cost of goods (365) - - (365) Sales and marketing costs (4,212) - - (4,212) Research and development - (24,559) - (24,559) General and administrative (1,338) (19,864) - (21,202) Segment loss from operations $ (4,122) $ (42,351) $ - $ (46,473) Segment assets $ 2,657 $ 103,225 $ 39,539 $ 145,421 Dermatology Pharmaceutical and ($ in thousands) Products Biotechnology Product Nine Months Ended September 30, 2015 Sales Development Consolidated Net Revenue $ - $ 525 $ 525 Direct cost of goods - - $ - Sales and marketing costs (1,632) - (1,632) Research and development - (24,054) (24,054) General and administrative (1,134) (11,610) (12,744) Segment loss from operations $ (2,766) $ (35,139) $ (37,905) Segment assets $ 1,593 $ 85,271 $ 86,864

Organization and Description 40

Organization and Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 09, 2016	Sep. 30, 2016	Apr. 27, 2016	Dec. 31, 2015
Organization And Nature Of Business [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.001		$ 0.001
National Holdings Corporation [Member]
Organization And Nature Of Business [Line Items]
Merger Agreement, Minimum percentage of Shares in Tender Offer to Completed Merger	56.00%
Business Acquisition, Share Price	$ 3.25		$ 3.25
Merger Agreement Termination Fee	$ 22.9
Common Stock Par Or Stated Value Per Share	$ 0.02		$ 0.02

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 09, 2016	Aug. 01, 2016	Dec. 31, 2015
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized	50.00%
Restricted Cash and Cash Equivalents	$ 15,500,000
Notes Payable	$ 14,900,000
Debt Instrument, Interest Rate, Stated Percentage	39.49%	9.00%
Contractual Obligation			$ 1,900,000
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year			1,100,000
Contractual Obligation, Due in Next Fiscal Year			$ 800,000
Deferred Revenue and Credits, Current	$ 1,007,000			$ 0
Allowance for Doubtful Accounts Receivable	0			$ 0
Deferred Clearing [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current	687,000
Marketing Credits [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current	321,000
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents	600,000
Hercules Note Payble [Member] | Third Party [Member]
Accounting Policies [Line Items]
Deferred financing costs	$ 15,000,000

National Holdings Corporation -

National Holdings Corporation - Fair value of assets acquired and liabilities assumed at the date of the acquisition (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Assets
Cash and cash equivalents:	$ 27,498
Accounts receivable	4,889
Cash deposits with clearing organizations	1,030
Receivable from brokers, dealers and clearing agencies	1,607
Securities owned, at fair value:	2,178
Prepaid expenses and other current assets	1,985
Property and equipment	1,132
Restricted cash	353
Goodwill	21,739		$ 0
Total assets	62,411
Liabilities
Accrued compensation payable	14,029
Accounts payable and accrued expenses	6,079
Deferred clearing and marketing credits	1,007
Other current liabilities	707
Total liabilities assumed	21,822
Non-controlling interests	17,717
Net assets acquired	22,872
Cash and cash equivalents from National	27,498
Cash to NHLD Shareholders (Tender Offer)	22,872
Net cash acquired in acquisition of National	$ (4,626)	$ 0

National Holdings Corporation43

National Holdings Corporation - Schedule of pro forma financial data assumes the acquisition (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Total revenues	$ 47,317	$ 42,360	$ 131,862	$ 126,976
Net loss attributable to common stockholders	$ (12,962)	$ (17,797)	$ (37,355)	$ (34,985)
Loss per share:
Basic	$ (0.32)	$ (0.45)	$ (0.94)	$ (0.90)
Diluted	$ (0.32)	$ (0.45)	$ (0.94)	$ (0.90)

National Holdings Corporation44

National Holdings Corporation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		9 Months Ended
	Sep. 30, 2016	Apr. 27, 2016	Sep. 30, 2016	Sep. 09, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Common Stock Par Or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Business Combination, Consideration Transferred			$ 22,872
Goodwill	$ 21,739		$ 21,739		$ 0
National Holdings Corporation [Member]
Business Acquisition [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.02		$ 0.02
Business Acquisition, Share Price		$ 3.25		$ 3.25
Number Of Shares Tendered		7
Business Acquisition, Percentage of Voting Interests Acquired	56.10%	56.00%	56.10%
Business Combination, Consideration Transferred	$ 22,900	$ 22,900

Broker-Dealers and Clearing O45

Broker-Dealers and Clearing Organizations and Other Receivables - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Sep. 09, 2016	Dec. 31, 2015
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 1,607,000		$ 0
Allowance for Doubtful Accounts Receivable	$ 0		$ 0
Forgivable Loan Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		$ 1,800,000
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		1,600,000
Allowance for Doubtful Accounts Receivable		782,000
Broker -Dealers And clearing Organisation [Member] | Forgivable Loan Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		1,800,000
Broker -Dealers And clearing Organisation [Member] | Other Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		$ 3,100,000

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Sep. 09, 2016
Loans and Leases Receivable Disclosure [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	39.49%	9.00%
Forgivable Loan Receivable [Member]
Loans and Leases Receivable Disclosure [Line Items]
Accounts Receivable, Net		$ 1.8

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2016	Sep. 09, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, net		$ 6,957	$ 1,132	$ 309
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		6,121		377
Less: Accumulated depreciation		(296)		(68)
Property and equipment, net		5,825		309
Computer Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 436		13
Useful Life (Years)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			65
Furniture and Fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 788		69
Useful Life (Years)		5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 259
Leasehold Improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 164		21
Useful Life (Years)		5 years
Construction in progress [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	[1]	$ 4,733		$ 274
Useful Life (Years)	[1]	15 years
[1]	For build-out of the Company's new office in New York, NY.

Property and Equipment - Schedu

Property and Equipment - Schedule Of Interest Expenses For Debt Arrangements (Detail) - USD ($) $ in Thousands	Sep. 09, 2016	Sep. 30, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, net	$ 1,132	$ 6,957	$ 309
Equipment [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Gross	532
Furniture And Fixtures [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Gross	65
Leaseholds And Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Gross	259
Assets Held under Capital Leases [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Gross	$ 276
National Holdings Corporation [Member] | Equipment [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years
National Holdings Corporation [Member] | Furniture And Fixtures [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years
National Holdings Corporation [Member] | Leaseholds And Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease
National Holdings Corporation [Member] | Assets Held under Capital Leases [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life	5 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property Plant And Equipment [Line Items]
Depreciation	$ 154,000	$ 6,000	$ 240,000	$ 17,000

Fair Value Measurements - Avenu

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail)	9 Months Ended
	Sep. 30, 2016
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.60%
Expected dividend yield	0.00%
Expected term in years	9 years 1 month 2 days
Expected volatility	83.00%
Probability of issuance of the warrant	50.00%
Mustang [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.60%
Expected dividend yield	0.00%
Expected term in years	9 years 9 months 4 days
Expected volatility	76.70%
Probability of issuance of the warrant	100.00%

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - Helocyte [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2016$ / shares	Sep. 30, 2016$ / shares
Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.64%
Expected dividend yield	0.00%
Probability of conversion	0.15%
Convertible Debt [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		1 year 6 months
Expected volatility		63.30%
Convertible Debt [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		1 year 3 months
Expected volatility		60.00%
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.64%
Expected dividend yield	0.00%
Strike price	$ 0.15	$ 0.15
Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		1 year 6 months
Expected volatility		63.30%
Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		1 year 3 months
Expected volatility		60.00%

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	$ 2,178	$ 0
Long-term investments, at fair value	685	2,485
Helocyte convertible note, at fair value	3,031	0
Total liabilities	3,982
Restricted Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	514
Corporate Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	114
Municipal Bonds [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	1,550
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	98	114
Warrant [Member] | Contingently Issuable Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	853
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	1,664
Long-term investments, at fair value	0	0
Helocyte convertible note, at fair value	0
Total liabilities	0
Fair Value, Inputs, Level 1 [Member] | Restricted Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 1 [Member] | Corporate Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	114
Fair Value, Inputs, Level 1 [Member] | Municipal Bonds [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	1,550
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member] | Contingently Issuable Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	514
Long-term investments, at fair value	0	0
Helocyte convertible note, at fair value	0
Total liabilities	0
Fair Value, Inputs, Level 2 [Member] | Restricted Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	514
Fair Value, Inputs, Level 2 [Member] | Corporate Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | Contingently Issuable Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	685
Long-term investments, at fair value	685	2,485
Helocyte convertible note, at fair value	3,031
Total liabilities	3,982
Fair Value, Inputs, Level 3 [Member] | Restricted Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 3 [Member] | Corporate Stock [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 3 [Member] | Municipal Bonds [Member] | National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value	0
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	98	$ 114
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | Contingently Issuable Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 853

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 6,845	$ 4,095	$ 2,599	$ 4,160
Additions during the period	5,928
Change in fair value of investments	(1,800)	(65)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	13
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	105
Balance	6,845	4,095	2,599	4,160
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	98		0
Additions during the period	98
Change in fair value of investments	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	0
Balance	98		0
Contingently Issuable Warrants [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	853		114
Additions during the period	634
Change in fair value of investments	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	105
Balance	853		114
Helocyte Convertible Note, At Fair Value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	3,031		0
Additions during the period	3,018
Change in fair value of investments	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	13
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	0
Balance	3,031		0
Investment In Laser Device [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250	250	250	250
Additions during the period	0
Change in fair value of investments	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	0
Balance	250	250	250	250
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	435	3,845	2,235	3,910
Additions during the period	0
Change in fair value of investments	(1,800)	(65)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	0
Balance	435	$ 3,845	2,235	$ 3,910
Securities Owned, At Fair value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,178		0
Additions during the period	2,178
Change in fair value of investments	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Derivative Liability, Gain Loss Included in Earnings	0
Balance	$ 2,178		$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2015	Mar. 17, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments		$ 250,000	$ 250,000		$ 250,000
Equity Method Investment, Ownership Percentage		35.00%
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total					1,800,000
Investment Owned, at Fair Value			2,178,000		$ 2,178,000		$ 0
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants					25.00%
Fair Value Adjustment of Warrants			$ 16,000	$ 0	$ 105,000	$ 0
Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 1.61		$ 1.61
Origo Acquisition Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value			$ 400,000		$ 400,000
Investments in Subsidiary, Number of Shares Transferred to Subsidiary					1,050,000
Fair Value Assumptions, Probability of Business Combination					31.89%
Investments In Subsidiary Number Of Shares Outstanding			265,000		265,000
Realized Investment Gains (Losses)					$ 25,000
Working Capital Note Convertible to Equity			$ 300,000		300,000
Unrealized Gain (Loss) on Investments					1,775,000
Common Stock Subject to Mandatory Redemption [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Assets			$ 31,700,000		$ 31,700,000
Non Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.16		$ 0.16
Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			0.04		$ 0.04
NSC Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Expiration Period					10 years
Fair Value Adjustment of Warrants	$ 3,000,000
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Exercise Price			11.50		$ 11.50
Fair Value Assumptions, Risk Free Interest Rate					1.14%
Fair Value Assumptions, Expected Volatility Rate					25.60%
Binomial Lattice Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			0.50		$ 0.50
Ghaidarov Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			0.13		0.13
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price			$ 5.04		$ 5.04
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement		$ 13,409,962
Percentage Of Shares Received Under Purchase Agreement		83.00%
Preferred Units, Issued		16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 28, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 1,000	$ 1,895	$ 3,143	$ 10,882
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	0	0	2,147
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		1,000	600	3,060	2,633
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	0	0	1,607
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 200	0	0	83	200
Escala [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	1,295	0	1,295
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 0	$ 0	$ 0	$ 3,000

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)	May 11, 2015	May 31, 2016	Feb. 29, 2016	Oct. 31, 2015	Sep. 30, 2015	Jul. 16, 2015	Jun. 17, 2015	May 31, 2015	Apr. 28, 2015	Mar. 31, 2015	Feb. 28, 2015	Sep. 30, 2016		Sep. 30, 2015	Sep. 30, 2016		Sep. 30, 2015	Dec. 31, 2015	Feb. 17, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets															$ 350,000		$ 1,250,000
Research And Development In Process												$ 1,000,000		$ 1,895,000	3,143,000		10,882,000
Stock Issued During Period, Value, Issued for Services															2,000		1,000
Research And Development Expense												7,316,000		$ 9,073,000	21,416,000		$ 13,172,000
Payments to Acquire in Process Research and Development				$ 200,000
Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						$ 22,600,000					$ 10,700,000
Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						7,000,000					26,200,000
NeuPharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process										$ 1,000,000
NeuPharma [Member] | Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due										40,000,000
NeuPharma [Member] | Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due										22,500,000
NeuPharma [Member] | Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due										$ 40,000,000
City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital										44.80%
Payments for Fees										$ 2,000,000
Stock Issued During Period, Shares, Other										1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										30.00%
Share Price										$ 0.147
Stock Issued During Period, Value, Other										$ 100,000
City Of Hope [Member] | Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									$ 1,500,000
City Of Hope [Member] | Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									13,000,000
National Institutes of Health [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Milestone Fees						700,000
New Zealand Pharmaceuticals Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursement Revenue						600,000
Dana-Farber [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Shares Issued, Price Per Share	$ 0.065
Stock Issued During Period, Shares, Issued for Services	500,000				136,830
Stock Issued During Period, Value, Issued for Services	$ 32,500				$ 600,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					5.00%									5.00%			5.00%
Proceeds from issuance of Common stock																	$ 10,000,000
Dana-Farber [Member] | First Commercial Sale Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												21,500,000			21,500,000
Dana-Farber [Member] | Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												60,000,000			60,000,000
Mustang Bio, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense												500,000		$ 1,500,000	500,000		1,000,000
Royalty Guarantees, Commitments, Amount												1,000,000			1,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners										10.00%
Royalty Revenue												300,000			1,300,000
Mustang Bio, Inc [Member] | Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due										$ 14,500,000
Mustang Bio, Inc [Member] | Financial Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due										2,000,000
Escala Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Fees						$ 1,300,000
Teva Pharmaceutical Industries Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Fees																		$ 500,000
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												206,500,000			206,500,000
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development and Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												220,000,000			220,000,000
Jubilant Biosys Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process												2,000,000
Revenue Recognition Milestone Method, Payments Due												87,500,000			87,500,000
Payment Of Upfront Licensing Fee		$ 2,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners								50.00%
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due		59,500,000
Jubilant Biosys Ltd [Member] | Successful Achievement Of One Preclinical Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												300,000			300,000
Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												25,500,000			25,500,000
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												61,700,000			61,700,000
Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												89,000,000			89,000,000
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone Method Revenue Additional Payments Eligible To Receive		89,000,000
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due		$ 89,000,000
Jubilant Biosys Ltd [Member] | TG Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment Of Upfront Licensing Fee															1,000,000
Collaboration Agreement with TGTX [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees												0		25,000	20,000		500,000	$ 500,000
Triplex [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Minimum Annual Royalty Payable									750,000
Triplex [Member] | City Of Hope [Member] | Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									9,000,000
Triplex [Member] | City Of Hope [Member] | Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									26,000,000
Pentameter [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Minimum Annual Royalty Payable									750,000
Pentameter [Member] | City Of Hope [Member] | Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									5,500,000
Pentameter [Member] | City Of Hope [Member] | Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due									26,000,000
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process												$ 0		$ 0	$ 0		$ 1,607,000
Payments for Fees											$ 900,000
Stock Issued During Period, Shares, Other											150,000
Research And Development Expense				$ 500,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					13.00%							13.00%		13.00%	13.00%		13.00%
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process												$ 1,000,000		$ 600,000	$ 3,060,000		$ 2,633,000
Reimbursement Of Cost Recognized As Revenue												$ 251,000			$ 732,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					20.00%							62.70%	[1]	20.00%	62.70%	[1]	20.00%
Checkpoint Therapeutics, Inc [Member] | First Commercial Sale Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												$ 21,500,000			$ 21,500,000
Checkpoint Therapeutics, Inc [Member] | Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												60,000,000			60,000,000
Checkpoint Therapeutics, Inc [Member] | Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												7,000,000			7,000,000
Checkpoint Therapeutics, Inc [Member] | Commercial Sales In Specified Territories [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due												14,500,000			14,500,000
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process									200,000			$ 0		$ 0	83,000		$ 200,000
Research And Development Expense															$ 35,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners												20.60%			20.60%
Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets			$ 35,000						$ 50,000	$ 155,000
Licensing Agreements [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital															44.50%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															30.00%
Share Price												$ 0.097			$ 0.097
Stock Issued During Period, Value, Other															$ 48,500
Licensing Agreements [Member] | City Of Hope [Member] | Common Class A [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued		500,000
Licensing Agreements [Member] | Dana-Farber [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees								$ 1,000,000
Licensing Agreements [Member] | Coronado SO [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital				44.80%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				30.00%
Share Price				$ 1.19
Licensing Agreements [Member] | IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets							$ 1,000,000
Payments for Fees											$ 2,000,000
Licensing Agreements [Member] | Helocyte [Member] | Common Class A [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued		8,333
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Shares Issued, Price Per Share																		$ 0.146
Research And Development Expense												$ 2,500			$ 11,500
Debt Instrument, Fee Amount																			$ 3,000,000
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Milestones and Sponsored Rese57

Milestones and Sponsored Research Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended		9 Months Ended
	Sep. 30, 2016	Aug. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Oct. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2015
Milestones and Sponsored Research Agreements [Line Items]
Payments to Acquire in Process Research and Development					$ 200
Research And Development Expense						$ 7,316	$ 9,073	$ 21,416	$ 13,172
Helocyte Inc [Member]
Milestones and Sponsored Research Agreements [Line Items]
Research And Development Expense						900		2,900
Payments For Research And Development Expenses		$ 2,000
Prepaid Research And Development	$ 1,100
Helocyte Inc [Member] | Pep Vax [Member]
Milestones and Sponsored Research Agreements [Line Items]
Payments For Research And Development Expenses		1,000
Prepaid Research And Development	500
Helocyte Inc [Member] | Triplex [Member]
Milestones and Sponsored Research Agreements [Line Items]
Payments For Research And Development Expenses		$ 1,000
Prepaid Research And Development	600
Mustang Bio, Inc [Member]
Milestones and Sponsored Research Agreements [Line Items]
Research And Development Expense						500	$ 1,500	500	$ 1,000
Research and Development Expense Payable, Milestone Payment										$ 2,000
UCLB [Member]
Milestones and Sponsored Research Agreements [Line Items]
Research and Development Expense Payable, Milestone Payment	$ 22,000					$ 22,000		22,000
Milestone Payments			$ 400
Payment of Upfront Fees								$ 100
UCLB [Member] | Maximum [Member]
Milestones and Sponsored Research Agreements [Line Items]
Royalty Percentage			5.00%
UCLB [Member] | Minimum [Member]
Milestones and Sponsored Research Agreements [Line Items]
Royalty Percentage			3.00%
City Of Hope [Member]
Milestones and Sponsored Research Agreements [Line Items]
Payments to Acquire in Process Research and Development			$ 1,000	$ 1,000
Research and Development Expense Payable, Milestone Payment			$ 2,000	$ 3,400

Intangibles, net - Additional I

Intangibles, net - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Jan. 31, 2016	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets				$ 350,000	$ 1,250,000
Cost of Goods Sold, Amortization				50,000	$ 0
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 50,000	$ 1,300,000		300,000
Cost of Goods Sold, Amortization			$ 29,000	$ 50,000

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 09, 2016	Dec. 31, 2015
Debt [Line Items]
Total notes payable, long-term	$ 30,168		$ 24,009
Less: Discount on notes payable	2,764		835
Total notes payable, long-term, net	$ 24,373		23,174
Interest Rate	39.49%	9.00%
IDB Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 14,929		14,009
Interest Rate	2.25%
Maturity Date	Feb - 2018
NSC Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 7,208		10,000
Interest Rate	8.00%
Maturity Date	Mar - 2018
Helocyte Convertible Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 3,031		0
Maturity Date	Dec - 2017
Helocyte Convertible Note [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Opsc Credit Facility [Member]
Debt [Line Items]
Total notes payable, long-term	$ 5,000		$ 0
Interest Rate	12.00%
Maturity Date	Sep - 2018

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt [Line Items]
Interest	$ 26	$ 0	$ 26	$ 0
Amortization of fees	28	0	28	0
Financing fees			491	0
Interest and Debt Expense, Total	54	0	54	0
Interest expense related to the Hercules loan	689	350	1,838	1,033
LOC Fees [Member]
Debt [Line Items]
Interest	3	0	10	0
Interest and Debt Expense, Total	3	0	10	0
IDB Note [Member]
Debt [Line Items]
Interest	84	82	243	235
Amortization of fees	0	1	1	3
Interest and Debt Expense, Total	84	83	244	238
NSC Debt [Member]
Debt [Line Items]
Interest	145	208	456	488
Amortization of fees	135	59	557	140
Interest and Debt Expense, Total	280	267	1,013	628
Ovamed [Member]
Debt [Line Items]
Interest	0	0	0	167
Interest and Debt Expense, Total	0	0	0	167
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest	26	0	26	0
Financing fees	242	0	491	0
Interest and Debt Expense, Total	$ 268	$ 0	$ 517	$ 0

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Feb. 29, 2016	Feb. 13, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 09, 2016	Jul. 31, 2016	Jul. 05, 2016	Dec. 31, 2015	Mar. 31, 2015
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	39.49%				39.49%		39.49%			9.00%
Fees related to the loan agreement							$ 491,000		$ 0
Notes Payable	$ 14,900,000				$ 14,900,000		14,900,000
Repayments of Debt			$ 2,800,000
Debt Instrument, Unamortized Discount	2,764,000				2,764,000		2,764,000						$ 835,000
Class of Warrant or Right, Discount On warrant	$ 1.9				$ 1.9		1.9
Helocyte Inc [Member]
Debt [Line Items]
Class of Warrant or Right, Value of Securities Called by Warrants or Rights							$ 301,800
Placement Fee,Percentage	0.00%				0.00%		0.00%
Helocyte Inc [Member] | Conversion One [Member]
Debt [Line Items]
Class of Warrant or Right, Value of Securities Called by Warrants or Rights							$ 100,000
Helocyte Inc [Member] | Conversion Two [Member]
Debt [Line Items]
Class of Warrant or Right, Value of Securities Called by Warrants or Rights							$ 201,800
Letter of Credit [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.00%				2.00%		2.00%
Letters of Credit Outstanding, Amount	$ 1.5				$ 1.5		$ 1.5
Israel Discount Bank Of New York [Member]
Debt [Line Items]
Debt Instrument, Face Amount				$ 15,000,000
Notes Payable	$ 14,900,000				$ 14,900,000		$ 14,900,000
IDB Promissory Note Payable [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.25%				2.25%		2.25%
Debt Instrument, Face Amount				15,000,000
IDB Promissory Note Payable [Member] | Minimum [Member]
Debt [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount				100,000
Opus Credit Facility [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%				12.00%		12.00%
Interest rate	12
Class of Warrant or Right, Value of Securities Called by Warrants or Rights	$ 1,500,000
Class of Warrant or Right, Exercise Price Percentage of Warrants or Rights					3.00%
Warrants and Rights Outstanding	$ 5				$ 5		$ 5
NSC Note [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%				8.00%		8.00%
Debt Instrument, Fee Amount													$ 900,000
Long-term Debt, Gross											$ 3,600,000	$ 3,600,000
Notes Payable														$ 10,000,000
Debt Instrument, Term							10 years
Debt Instrument, Interest Rate, Effective Percentage													12.40%
Contingently Issuable Warrants Percentage	25.00%				25.00%		25.00%				25.00%
NSC Note [Member] | Issuable Warrant [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount	$ 634,000				$ 634,000		$ 634,000
NSC Note [Member] | Warrant [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total	$ 114,000				114,000		114,000
Long-term Debt, Fair Value			174,000
Hercules Note Payble [Member]
Debt [Line Items]
Fees related to the loan agreement					$ 242,000	$ 0	$ 491,000		$ 0
Debt Instrument, Periodic Payment, Interest				100,000
Debt Instrument, Periodic Payment				$ 14,000,000
Helocyte Convertible Note [Member]
Debt [Line Items]
Debt Instrument, Term							18 months
Proceeds from Issuance or Sale of Equity							$ 10,000,000
Legal Fees								$ 25,000,000
Class of Warrant or Right, Exercise Price Percentage of Warrants or Rights							110.00%
Helocyte Convertible Note [Member] | Conversion One [Member]
Debt [Line Items]
Debt Instrument, Convertible, Terms of Conversion Feature		the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.
Helocyte Convertible Note [Member] | Conversion Two [Member]
Debt [Line Items]
Debt Instrument, Convertible, Terms of Conversion Feature		a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
Helocyte Convertible Note [Member] | Minimum [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.00%				5.00%		5.00%
Helocyte Convertible Note [Member] | Maximum [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%				8.00%		8.00%
Debt Instrument, Face Amount	$ 5,000,000				$ 5,000,000		$ 5,000,000
NSC [Member]
Debt [Line Items]
Debt Instrument, Term							10 years
Checkpoint [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total			$ 324,000
Checkpoint [Member] | NSC Note [Member]
Debt [Line Items]
Fees related to the loan agreement							$ 2,800,000
Avenue [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total	$ 370,000				$ 370,000		370,000
Avenue [Member] | NSC Note [Member]
Debt [Line Items]
Fees related to the loan agreement							$ 3,600,000

Accrued Expenses and Other Lo62

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued expenses:
Professional fees	$ 1,389	$ 382
Salaries, bonuses and related benefits	1,777	2,492
Ovamed manufacturing rights - short term component	750	1,500
Research and development	788	810
Dr. Falk Pharma milestone	2,802	2,717
Accrued royalty and coupons	301	0
Lease impairment	95	146
Other	703	523
Total accrued expenses	8,605	8,570
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	4,583	584
Total other long-term liabilities	$ 4,583	$ 584

Accrued Expenses and Other Lo63

Accrued Expenses and Other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Legal	$ 1,389	$ 382
Other	703	523
Total	21,831	$ 10,438
National Holdings Corporation [Member]
Legal	961
Audit	196
Telecommunications	181
Data Services	229
Regulatory	365
Settlements	701
Deferred rent	39
Contingent consideration payable	423
Other	2,984
Total	$ 6,079

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended			12 Months Ended
	Sep. 30, 2016		Sep. 30, 2015	Sep. 30, 2016		Sep. 30, 2015	Dec. 31, 2015
Noncontrolling Interest [Line Items]
NCI equity share				$ 50,539			$ 32,882
Net loss attributed to non-controlling interests	$ (3,975)		$ (1,694)	(12,324)		$ (2,416)	(5,455)
Non-controlling interests in consolidated entities	38,215			38,215			27,427
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(494)			6
Net loss attributed to non-controlling interests	(47)		(367)	(231)		(401)	(567)
Non-controlling interests in consolidated entities	(725)			(725)			(561)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(217)			23
Net loss attributed to non-controlling interests	(4)		(7)	(14)		(237)	(240)
Non-controlling interests in consolidated entities	(231)			(231)			(217)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				1,337			14
Net loss attributed to non-controlling interests	(204)		(54)	(363)		(321)	(373)
Non-controlling interests in consolidated entities	974			974			(359)
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				33,004			32,760
Net loss attributed to non-controlling interests	(3,254)	[1]	(977)	(10,767)	[1]	(1,168)	(3,855)
Non-controlling interests in consolidated entities	22,237			22,237			28,905
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(277)			79
Net loss attributed to non-controlling interests	(104)		$ (289)	(333)		$ (289)	(420)
Non-controlling interests in consolidated entities	(610)			(610)			$ (341)
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(531)
Net loss attributed to non-controlling interests	(362)			(616)
Non-controlling interests in consolidated entities	(1,147)			(1,147)
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share				17,717
Net loss attributed to non-controlling interests				0
Non-controlling interests in consolidated entities	$ 17,717			$ 17,717
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Non-Controlling Interests - S65

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended			12 Months Ended
	Sep. 30, 2016		Sep. 30, 2015	Sep. 30, 2016		Sep. 30, 2015	Dec. 31, 2015
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (3,975)		$ (1,694)	$ (12,324)		$ (2,416)	$ (5,455)
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (47)		$ (367)	$ (231)		$ (401)	(567)
Non-controlling ownership	10.50%		11.50%	10.50%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (4)		$ (7)	$ (14)		$ (237)	(240)
Non-controlling ownership	13.00%		13.00%	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (204)		$ (54)	$ (363)		$ (321)	(373)
Non-controlling ownership	23.90%		10.00%	23.90%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (3,254)	[1]	$ (977)	$ (10,767)	[1]	$ (1,168)	(3,855)
Non-controlling ownership	62.70%	[1]	20.00%	62.70%	[1]	20.00%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (104)		$ (289)	$ (333)		$ (289)	$ (420)
Non-controlling ownership	8.10%		25.00%	8.10%		25.00%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (362)			$ (616)
Non-controlling ownership	20.60%			20.60%
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	13,644,367	10,154,952	13,767,873	9,757,654
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	392,731	685,061	480,559	685,061
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,700,000	0	1,700,000	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,761,032	1,832,499	1,769,426	2,019,219
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	8,705,136	6,884,631	8,763,797	6,795,132
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,085,468	752,761	1,054,091	258,242

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	13,644,367	10,154,952	13,767,873	9,757,654
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount			8,705,137

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 2,903	$ 8,501	$ 8,792	$ 11,896
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1]	963	2,966	3,293	3,359
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		1,937	3,296	5,490	6,284
Executive Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		0	2,229	0	2,229
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 3	$ 10	$ 9	$ 24
[1]	Consists of approximately $5,000 of Avenue's compensation expenses, approximately $0.8 million of Checkpoint's compensation expense, approximately $130,000 of JMC's compensation expenses and approximately $67,000 of Helocyte's compensation expenses on stock grants for the three months ended September 30, 2016, and approximately $23,000 of Avenue's compensation expenses, approximately $2.7 million of Checkpoint's compensation expense, approximately $458,000 of JMC's compensation expenses and approximately $160,000 of Helocyte's compensation expenses on stock grants for the nine months ended September 30, 2016. Consists of approximately $15,000 of Avenue's compensation expenses, approximately $2.1 million of Checkpoint's compensation expense and approximately $279,000 of JMC's compensation expenses on stock grants for the three months ended September 30, 2015, and approximately $38,000 of Avenue's compensation expenses, approximately $2.1 million of Checkpoint's compensation expense, approximately $279,000 of JMC's compensation expenses and approximately $147,000 of Mustang's compensation expenses on stock grants for the nine months ended September 30, 2015.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options vested and expected to vest	1,779,365
Number of shares, Options granted	0
Number of shares, Options Forfeited	(648,864)
Number of shares, Options vested and expected to vest	1,130,501	1,779,365
Number of shares, Options vested and exercisable	1,065,501
Weighted average exercise price, options vested and expected to vest	$ 4.37
Weighted average exercise price, options granted	0
Weighted average exercise price, options Forfeited	0.51
Weighted average exercise price, options vested and expected to vest	3.73	$ 4.37
Weighted average exercise price, options vested and exercisable	$ 3.77
Total weighted average intrinsic value, options vested and expected to vest	$ 745,069	$ 666,396
Total weighted average intrinsic value, options granted	0
Total weighted average intrinsic value, options Forfeited	0
Total weighted average intrinsic value, options vested and expected to vest	745,069	$ 666,396
Total weighted average intrinsic value, options vested and exercisable	$ 710,269
Weighted average remaining contractual life,oOptions vested and expected to vest	5 years 2 months 5 days	6 years 3 months 25 days
Weighted average remaining contractual life,oOptions vested and exercisable	5 years 29 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance | shares	8,757,935
Number of shares, Restricted stock granted | shares	1,240,868
Number of shares, Restricted units cancelled | shares	(33,333)
Number of shares, Restricted stock vested | shares	(173,333)
Number of shares, Restricted stock units granted | shares	526,000
Number of shares, Restricted stock units cancelled | shares	(101,750)
Number of shares, Restricted stock units vested | shares	(223,375)
Number of shares, Unvested balance | shares	9,993,012
Weighted average grant price, Unvested balance | $ / shares	$ 2.47
Weighted average grant price, Restricted stock granted | $ / shares	2.77
Weighted average grant price, Restricted stock cancelled | $ / shares	2.69
Weighted average grant price, Restricted stock vested | $ / shares	2.73
Weighted average grant price, Restricted stock units granted | $ / shares	2.92
Weighted average grant price, Restricted stock units cancelled | $ / shares	3.64
Weighted average grant price, Restricted stock units vested | $ / shares	3.56
Weighted average grant price, Unvested balance | $ / shares	$ 2.49

Stockholders' Equity - summariz

Stockholders' Equity - summarizes Fortress warrant activities (Detail) - Warrant [Member] - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2016	Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding		569,835
Number of shares, Granted		1,800,000
Number of shares, Expired		(161,382)
Number of shares, Exercised	[1]	(25,000)
Number of shares, Outstanding		2,183,453	569,835
Number of shares, Exercisable		383,453
Weighted average exercise price, Outstanding		$ 6.31
Weighted average exercise price, Granted		3
Weighted average exercise price, Expired		6.3
Weighted average exercise price, Exercised	[1]	1.37
Weighted average exercise price, Outstanding		3.64	$ 6.31
Weighted average exercise price, Exercisable		$ 6.63
Total weighted average instrinsic value, Outstanding		$ 96,000	$ 120,700
Total weighted average intrinsic value, Granted		0
Total weighted average intrinsic value, Expired		0
Total weighted average intrinsic value, Exercised	[1]	40,000
Total weighted average instrinsic value, Outstanding		96,000	$ 120,700
Total weighted average intrinsic value, Exercisable		$ 96,000
Weighted average remaining contractual life (years), Outstanding		5 years 2 months 1 day	1 year 10 months 2 days
Weighted average remaining contractual life (years), Granted		5 years 10 months 20 days
Weighted average remaining contractual life, Exercisable (years)		1 year 9 months 14 days
[1]	cashless

Stockholders' Equity - Fair val

Stockholders' Equity - Fair value of options (Detail) - Journey Medical Corporation [Member]	9 Months Ended
	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.14%
Risk-free interest rate, Maximum	1.82%
Expected dividend yield	0.00%
Expected volatility, Minimum	95.25%
Expected volatility, Maximum	104.76%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years 1 month 10 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 11 months 12 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Jul. 15, 2016	Jul. 15, 2015	Sep. 30, 2016	May 31, 2016	Mar. 30, 2016	Feb. 29, 2016	Feb. 23, 2016	Jan. 31, 2016	Mar. 31, 2015	Feb. 28, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	May 26, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation weighted-average vesting period													2 months 19 days
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period			85.00%								85.00%		85.00%
Employee Stock Purchase Plan to eligible employees, compensation expense recognized											$ 30,000	$ 13,000	$ 56,000	$ 28,000
Common Stock issued in connection with the first ESPP offering													33,958
Research And Development Expense											7,316,000	9,073,000	$ 21,416,000	13,172,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross													0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 16,000								16,000		$ 16,000
Share-based Compensation													8,792,000	11,896,000
Stock Issued During Period, Shares, New Issues							10,000
Stock Issued During Period, Value, Employee Stock Purchase Plan													81,000
Payments of Stock Issuance Costs													49,000	0
Stock Issued During Period, Value, New Issues											53,000,000
Long-Term Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding		500,000
Weighted Market Value Percentage of Invested Capital	44.80%
Weighted Average Cost Percentage of Capital	30.00%
Capital Units, Authorized								100,000,000
Share-based Compensation											75,000		200,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Shares Granted								1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total		$ 2,200,000
Checkpoint s 2015 Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate															1.50%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross									1,500,000
Checkpoint [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 7
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total							$ 126,640
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							3,500
Warrant Purchase Price Per Unit							$ 45,000
Warrants Issued							44,324
Proceeds from Issuance of Private Placement							$ 600,000
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross						1,900,000				3,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost						$ 400,000
Dr. Rosenwald [Member] | Long-Term Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								510,434
Mr. Weiss [Member] | Long-Term Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 2,400,000
Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense														147,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, compensation expense recognized											5,000	15,000	23,000	38,000
Research And Development Expense											2,500		11,500
Allocated Share-based Compensation Expense											$ 800,000	2,100,000	$ 2,700,000	2,100,000
Weighted Market Value Percentage of Invested Capital															44.80%
Weighted Average Cost Percentage of Capital															30.00%
Shares Issued, Price Per Share															$ 0.146
Share-based Compensation												$ 13,000		$ 16,000
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services															1,000,000
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage															50.00%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage															12.50%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage															50.00%
Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8.50								$ 8.50		$ 8.50
Stock Issued During Period Shares warrants Exercised			2,500
Stock Issued During Period, Value of Warrants Excercised			$ 65,000
Stock Issued During Period, Value, New Issues			$ 12,400,000
Private Placement Stock Units, Shares To Be Issued			10,000								10,000		10,000
Warrant Expiration Term			5 years
Warrants Issued During Period			478,708
Journey Medical Corporation [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period													4 years
Journey Medical Corporation [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period													3 years
Journey Medical Corporation [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Market Value Percentage of Invested Capital													44.20%
Weighted Average Cost Percentage of Capital													25.10%
Shares Issued, Price Per Share			$ 0.53								$ 0.53		$ 0.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total													310,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate													0.00%
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate															83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate													1.35%
Share Price												$ 0.065		$ 0.065	$ 4.39	$ 4.42
Fair Value Assumptions, Weighted Average Volatility Rate														30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														48 months
Weighted Average Cost Percentage of Capital									44.80%
Fair Value Assumptions, Risk Free Interest Rate													83.00%
Share-based Compensation												$ 2,100,000		$ 2,100,000
JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense											$ 130,000	279,000	$ 458,000	279,000
Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research And Development Expense											900,000		2,900,000
Allocated Share-based Compensation Expense											$ 67,000		$ 160,000
Helocyte Inc [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				68.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.30%
Share Price				$ 0.46
Stock Issued During Period, Shares, Issued for Services				508,333	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				127,084
Helocyte Inc [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price			$ 0.097								$ 0.097		$ 0.097
Stock Issued During Period, Shares, Issued for Services					1,000,000
Share-based Compensation											$ 17,000
Helocyte Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation											50,000		$ 118,000
National Holdings Corporation [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee			10.00%
Payments of Stock Issuance Costs			$ 1,200,000
Warrants Issued During Period			191,483
Percentage Of Shares Issued To Placement Agent			10.00%
Research and Development Expense [Member] | Checkpoint s 2015 Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation											20,000		20,000
Research and Development Expense [Member] | Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense											400,000		1,600,000
General and Administrative Expense [Member] | Incentive Plan 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation													$ 1,000,000
General and Administrative Expense [Member] | Checkpoint s 2015 Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation											300,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation weighted-average vesting period													2 years 2 months 12 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 5,600,000								5,600,000		$ 5,600,000
Share-based Compensation												0		22,000
Restricted Stock [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation											29,000		$ 95,000
Restricted Stock [Member] | General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation												$ 279,000		$ 279,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation weighted-average vesting period													1 year 4 months 24 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 1,200,000								$ 1,200,000		$ 1,200,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock issued in connection with the first ESPP offering													125,150
Common Stock, Capital Shares Reserved for Future Issuance			74,850								74,850		74,850
Employee Stock Option [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation											$ 100,000		$ 400,000

Commitments and Contingencies -

Commitments and Contingencies - Total future minimum lease payments (Detail) $ in Thousands	Sep. 30, 2016USD ($)
Operating Leased Assets [Line Items]
Rental Expense, 2017	$ 3,015
Rental Expense, 2018	2,253
Rental Expense, 2019	1,462
Rental Expense, 2020	1,298
Rental Expense, 2021	1,004
Rental Expense, Thereafter	2,062
Rental Expense,Total	11,094
Less, Sublease Income, 2017	84
Less, Sublease Income, 2018	0
Less, Sublease Income, 2019	0
Less, Sublease Income, 2020	0
Less, Sublease Income, 2021	0
Less, Sublease Income, Thereafter	0
Less, Sublease Income, Total	84
Net, 2017	2,931
Net, 2018	2,253
Net, 2019	1,462
Net, 2020	1,298
Net, 2021	1,004
Net, Thereafter	2,062
Net, Total	$ 11,010

Commitments and Contingencies75

Commitments and Contingencies - Additional Information (Detail)	Sep. 30, 2016USD ($)
Letter of Credit [Member] | National Holdings Corporation [Member]
Operating Leased Assets [Line Items]
Collateralized Agreements	$ 194,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Mar. 13, 2015	Sep. 30, 2016	Jul. 26, 2016	May 31, 2016	Apr. 27, 2016	May 31, 2015	Mar. 20, 2015	Mar. 17, 2015	Feb. 17, 2015	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Jul. 31, 2016	Jul. 05, 2016	Mar. 17, 2014
Related Party Transaction [Line Items]
Costs and Expenses, Related Party											$ 0	$ 66,000	$ 84,000	$ 154,000
Agreement Description Terms	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) monthly net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).						(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Helocyte’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to 2.5%  of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
Debt Issuance Cost													491,000	0
Lease Sharing Agreements, Contributions to Property Under Lease													4,700,000
Equity Method Investment, Ownership Percentage																		35.00%
Business Combination, Consideration Transferred													$ 22,872,000
National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		56.10%			56.00%						56.10%		56.10%
Proceeds from Fees Received											$ 1,300,000	1,300,000	$ 1,300,000	1,300,000
Business Combination, Consideration Transferred		$ 22,900,000			$ 22,900,000
NSC Note [Member]
Related Party Transaction [Line Items]
Long-term Debt, Gross																$ 3,600,000	$ 3,600,000
Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party						$ 10,000
Board of Directors Chairman [Member] | National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		4.60%									4.60%		4.60%
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense										$ 1,100,000
Prepaid Rent		$ 180,000									$ 180,000		$ 180,000
Due from Related Parties, Current		2,600,000									2,600,000		2,600,000
Percentage of Rentable Area				45.00%						40.00%
Lease Improvement Cost Associate With Lease													5,100,000
Checkpoint [Member] | NSC Note [Member]
Related Party Transaction [Line Items]
Debt Issuance Cost													2,800,000
Checkpoint [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party						7,500
Founders Agreement [Member] | Mustang Bio, Inc [Member]
Related Party Transaction [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract			15 years
Agreement Description Terms			Concurrently with the second amendment to the Founders Agreement, we entered into an Exchange Agreement whereby we exchanged our 7.2 million Class B Common shares for 7.0 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A Common Stock and the Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at our option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, we will receive on each March 13 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustang’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.
Debt Instrument, Face Amount			$ 2,000,000
OPPM [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense										$ 500,000
Prepaid Rent		37,000									37,000		37,000
Due from Related Parties, Current		$ 600,000									600,000		600,000
Percentage of Rentable Area				10.00%						20.00%
Lease Improvement Cost Associate With Lease													5,100,000
Collaboration Agreement with TGTX [Member]
Related Party Transaction [Line Items]
Payments for Fees											0	25,000	20,000	500,000	$ 500,000
Founder [Member] | Founders Agreement [Member]
Related Party Transaction [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract							15 years		15 years
Management Services Agreement [Member]
Related Party Transaction [Line Items]
Annual Consulting Fee	$ 500,000						$ 500,000	$ 500,000	$ 500,000
Increase in Annual Consulting Fee	1,000,000						1,000,000	1,000,000	1,000,000
Excess In Net Assets Value	$ 100,000,000						$ 100,000,000	100,000,000	100,000,000
Management Services Agreement [Member] | Checkpoint [Member]
Related Party Transaction [Line Items]
Long-term Debt, Gross								$ 2,800,000
Management Services Agreement [Member] | Founders Agreement [Member]
Related Party Transaction [Line Items]
Debt Issuance Cost									$ 3,000,000
Avenue [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party						$ 5,000
Avenue [Member] | Founders Agreement [Member]
Related Party Transaction [Line Items]
Agreement Description Terms							Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class B Common shares for 6.75 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Helocyte common stock and (B) the whole shares of Helocyte common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Helocyte common stock, subject to certain adjustments. As the sole holder of Class A Preferred Stock, the Company will receive on each March 20 (each a PIK Dividend Payment Date) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (PIK Dividends) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Helocytes fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.		the Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class A Common shares for approximately 7.5 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights, election of directors and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Avenue common stock and (B) the whole shares of Avenue common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Avenue common stock, subject to certain adjustments. For a period of 10 years from the date of the first issuance of Class A Preferred Stock, the holders of record of shares of Class A Preferred Stock, exclusively and as a separate class, are entitled to appoint or elect the majority of Avenues Board of Directors. As holders of Class A Preferred Stock, the Company will receive on each February 17 (each a PIK Dividend Payment Date) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (PIK Dividends) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Avenues fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.
Shared Services Agreement [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement												$ 71,800		$ 71,800
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement											$ 300,000		600,000
Desk Space Agreements [Member]
Related Party Transaction [Line Items]
Payments for Rent													$ 400,000

Net Capital Requirements of B77

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail)	Sep. 30, 2016USD ($)
National Securities [Member]
Net Capital	$ 5,600,000
Excess Net Capital at 1000 Percent	5,400,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	250,000
vFinance Investments [Member]
Net Capital	2,200,000
Excess Net Capital at 1000 Percent	1,200,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000
Percentage Of Aggregate Indebtness To Net Capital	77.90%

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net Revenue	$ 975	$ 25	$ 3,865	$ 525
Direct cost of goods	41	0	365	0
Sales and marketing costs	(1,244)	(950)	(4,212)	(1,632)
Research and development	7,316	9,073	21,416	13,172
General and administrative	8,864	7,129	25,414	14,376
Segment loss from operations	(16,246)	(18,072)	(46,473)	(37,905)
Segment assets	145,421	86,864	145,421	86,864	$ 118,610
Dermatology Product Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue	429	0	1,793	0
Direct cost of goods	(41)		(365)	0
Sales and marketing costs	(1,244)	(950)	(4,212)	(1,632)
Research and development	0	0	0	0
General and administrative	(422)	(516)	(1,338)	(1,134)
Segment loss from operations	(1,278)	(1,466)	(4,122)	(2,766)
Segment assets	2,657	1,593	2,657	1,593
Pharmaceutical and Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue	546	25	2,072	525
Direct cost of goods	0		0	0
Sales and marketing costs	0	0	0
Research and development	(8,316)	(10,968)	(24,559)	(24,054)
General and administrative	(7,198)	(5,663)	(19,864)	(11,610)
Segment loss from operations	(14,968)	(16,606)	(42,351)	(35,139)
Segment assets	103,225	$ 85,271	103,225	$ 85,271
Financial Service Activities [Member]
Segment Reporting Information [Line Items]
Net Revenue	0		0
Direct cost of goods	0		0
Sales and marketing costs	0		0
Research and development	0		0
General and administrative	0		0
Segment loss from operations	0		0
Segment assets	$ 39,539		$ 39,539

Segment Information - Additiona

Segment Information - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$ 429,000	$ 0	$ 1,793,000	$ 0
Customer One [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	200,000		800,000
Accounts Receivable, Net	100,000		100,000
Customer Two [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	43,000		300,000
Accounts Receivable, Net	71,000		71,000
Customer Three [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net			300,000
Accounts Receivable, Net	$ 50,000		$ 50,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	1 Months Ended				9 Months Ended
	Oct. 31, 2016	Oct. 25, 2016	Sep. 30, 2016	Feb. 23, 2016	Sep. 30, 2016	Sep. 30, 2015	Jul. 31, 2016	Jul. 05, 2016	Mar. 17, 2014
Subsequent Event [Line Items]
Payments of Stock Issuance Costs					$ 49,000	$ 0
Stock Issued During Period, Shares, New Issues				10,000
Equity Method Investment, Ownership Percentage									35.00%
National Holdings Corporation [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Payments of Stock Issuance Costs			$ 1,200,000
Percentage Of Placement Agent Fee			10.00%
Percentage Of Shares Issued To Placement Agent			10.00%
NSC Note [Member]
Subsequent Event [Line Items]
Long-term Debt, Gross							$ 3,600,000	$ 3,600,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		10,000
Subsequent Event [Member] | Private Placement [Member] | Mustang Bio, Inc [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 8.50
Warrant Purchase Price Per Unit		$ 65,000
Warrant Expiration Term		5 years
Warrants Issued		272,645
Subsequent Event [Member] | National Holdings Corporation [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Private Placement		$ 7,100,000
Payments of Stock Issuance Costs		$ 700,000
Percentage Of Placement Agent Fee		10.00%
Warrants Issued		109,058
Percentage Of Shares Issued To Placement Agent		10.00%
Subsequent Event [Member] | University Of Texas Health Science Centerat Houston [Member] | Cellvation [Member]
Subsequent Event [Line Items]
Upfront fee	$ 300,000
Equity Method Investment, Ownership Percentage	5.00%
Subsequent Event [Member] | NSC Note [Member]
Subsequent Event [Line Items]
Long-term Debt, Gross		$ 3,600,000
Subsequent Event [Member] | Helocyte Convertible Note [Member] | Helocyte Inc [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Private Placement	$ 1,000,000
Payments of Stock Issuance Costs	$ 100,000
Warrants Issued		138,462